{"title":"Buscopan","description":"\u003cp data-start=\"350\" data-end=\"770\" class=\"\"\u003eAntispasmodic drugs based on scopolamine butylbromide and ibuprofen indicated for the treatment of abdominal pain, intestinal colic, menstrual cramps and spasms of the gastrointestinal or urinary tract. Available in coated tablets and rapidly absorbed formulations for effective and prolonged relief. Targeted action on smooth muscles to reduce spasms and tension. Fast shipping in 24\/48 hours.\u003c\/p\u003e","products":[{"product_id":"buscofen-12-capsule-molli-200mg","title":"Buscofen 12 Soft Capsules 200mg","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBuscofen 12 Soft Capsules is a drug based on\u003c\/span\u003e \u003cspan\u003eibuprofen\u003c\/span\u003e \u003cspan\u003e(200 mg per capsule), an active ingredient belonging to the category of nonsteroidal anti-inflammatory drugs (NSAIDs), indicated for the treatment of\u003c\/span\u003e \u003cspan\u003epain of various origins\u003c\/span\u003e \u003cspan\u003e. It is particularly effective for relieving pain related to conditions such as\u003c\/span\u003e \u003cspan\u003emenstrual pain\u003c\/span\u003e \u003cspan\u003e,\u003c\/span\u003e \u003cspan\u003eheadache\u003c\/span\u003e \u003cspan\u003e,\u003c\/span\u003e \u003cspan\u003etoothache\u003c\/span\u003e \u003cspan\u003e,\u003c\/span\u003e \u003cspan\u003eneuralgia\u003c\/span\u003e \u003cspan\u003e, and\u003c\/span\u003e \u003cspan\u003eosteoarticular\u003c\/span\u003e \u003cspan\u003eand\u003c\/span\u003e \u003cspan\u003emuscular\u003c\/span\u003e pain \u003cspan\u003e. Thanks to its formulation in\u003c\/span\u003e \u003cspan\u003esoft capsules\u003c\/span\u003e \u003cspan\u003e, it is rapidly absorbed by the body, offering faster relief than other solid formulations.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eBuscofen 12 Soft Capsules is indicated for the symptomatic treatment of mild to moderate pain, including:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eMenstrual cramps\u003c\/span\u003e \u003cspan\u003e(dysmenorrhea);\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n \u003cp role=\"presentation\" dir=\"ltr\"\u003e\u003cspan\u003eHeachache\u003c\/span\u003e \u003cspan\u003e;\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eToothache\u003c\/span\u003e \u003cspan\u003e;\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eNeuralgia\u003c\/span\u003e \u003cspan\u003e;\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eMuscle and joint pain\u003c\/span\u003e \u003cspan\u003e(such as lumbago, back pain and arthralgia);\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eRheumatic\u003c\/span\u003e \u003cspan\u003eand inflammatory pain of musculoskeletal origin.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Buscofen 12 Soft Capsules 200mg - What is the active ingredient of Buscofen 12 Soft Capsules 200mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eCoated tablets, 1 tablet contains: ibuprofen 200 mg. Soft gelatin capsules: 1 soft capsule contains: ibuprofen 200 mg. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Buscofen 12 Soft Capsules 200mg - What does Buscofen 12 Soft Capsules 200mg contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eCoated tablets - blister pack of 20 tablets: corn starch, sodium carboxymethyl starch, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol 6000, talc, titanium dioxide, antifoam emulsion. Soft capsules - blister pack of 12 or 24 capsules: macrogol 600, potassium hydroxide, purified water, gelatin, partially dehydrated liquid sorbitol.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eDIRECTIONS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Buscofen 12 Soft Capsules 200mg - Why is Buscofen 12 Soft Capsules 200mg used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePain of various origins and natures (menstrual pain, headache, toothache, neuralgia, osteoarticular and muscular pain).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Buscofen 12 Soft Capsules 200mg - When should Buscofen 12 Soft Capsules 200mg not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients. Subjects with hypersensitivity to acetylsalicylic acid or other analgesics, antipyretics, nonsteroidal anti-inflammatory drugs (NSAIDs), in particular when hypersensitivity is associated with nasal polyposis, angioedema and\/or asthma. Severe hepatic insufficiency. Severe renal insufficiency (glomerular filtration rate less than 30 ml\/min). Severe cardiac insufficiency (NYHA class IV). Subjects with blood dyscrasias of unknown origin, porphyria, hypertension, severe uncontrolled coronary insufficiency. Severe or active peptic ulcer. History of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). Subjects with clinical conditions that determine an increased tendency to bleeding. In conjunction with surgical procedures (including dental operations). Subjects who have undergone significant fluid loss (through vomiting, diarrhoea or insufficient fluid intake). During the third trimester of pregnancy (see section 4.6). Children under 12 years of age.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Buscofen 12 Soft Capsules 200mg - How to take Buscofen 12 Soft Capsules 200mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDo not administer to children under 12 years of age. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration of treatment necessary to control symptoms (see section 4.4). Coated tablets. Adults and adolescents over 12 years: 1-2 tablets, two - three times a day, preferably on a full stomach. However, do not exceed the dose of 1200 mg (6 tablets) per day. Do not exceed the recommended doses. If the use of the medicine is necessary for more than 3 days in adolescents, or in the event of worsening of symptoms, a doctor should be consulted. Elderly: elderly patients should stick to the minimum doses indicated. Patients with renal insufficiency: in the presence of renal insufficiency, elimination may be reduced and the dosage should be adjusted accordingly. Soft capsules. Adults and adolescents over 12 years: 1-2 soft capsules, two - three times a day, preferably on a full stomach. Do not exceed the dose of 1200 mg (6 soft capsules) per day. Do not exceed the recommended doses. If the use of the medicine is necessary for more than 3 days in adolescents, or in case of worsening of the symptoms, a doctor must be consulted. Elderly: elderly patients must stick to the minimum doses indicated. Patients with renal insufficiency: in the presence of renal insufficiency, elimination may be reduced and the dosage must be adjusted accordingly. Buscofen must not be used for more than 7 days. If higher doses are necessary or if a more prolonged treatment is required, then it is necessary to contact your doctor. The coated tablets and soft capsules must be swallowed without chewing, preferably with a little water. It is recommended to take them during or after meals, especially for people with gastric disorders.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Buscofen 12 Soft Capsules 200mg - How to store Buscofen 12 Soft Capsules 200mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eCoated tablets - blister pack of 20 tablets: store at room temperature. Soft capsules - blister pack of 12 or 24 capsules: no storage conditions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eWARNINGS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Buscofen 12 Soft Capsules 200mg - About Buscofen 12 Soft Capsules 200mg it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe use of Buscofen with concomitant NSAIDs, including cyclooxygenase-2 (COX-2) selective inhibitors, should be avoided due to an increased risk of ulceration or bleeding (see section 4.5). Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see sections below on gastrointestinal and cardiovascular risks). Paediatric population: There is a risk of impaired renal function in dehydrated adolescents. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2). Gastrointestinal bleeding, ulceration and perforation: Gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest dose available. The concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients and also for patients who are taking low dose acetylsalicylic acid or other drugs likely to increase gastrointestinal risk (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding), particularly in the initial stages of treatment. Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors (SSRIs) or anti-platelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients receiving Buscofen, the treatment should be withdrawn. NSAIDs should be given with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Use with caution in patients with coagulation defects. Cardiovascular and cerebrovascular effects: Appropriate monitoring and advice are necessary in patients with a history of hypertension and\/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a small increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low doses of ibuprofen (e.g. \u0026lt;= 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses (2400 mg\/day) of ibuprofen are required. Severe skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk early in the course of therapy, with the onset of the reaction occurring in the majority of cases within the first month of treatment. Acute generalised exanthematous pustulosis (AGEP) has been reported in connection with medicinal products containing ibuprofen. Treatment with Buscofen should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Masking of symptoms of underlying infections: Buscofen may mask the symptoms of infection, which may delay the initiation of adequate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of varicella. When Buscofen is administered for the relief of infection-related fever or pain, monitoring for infection is advised. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. Renal effects: Caution should be exercised in patients with considerable dehydration when initiating treatment with ibuprofen.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Buscofen 12 Soft Capsules 200mg - Which medicines or foods can modify the effect of Buscofen 12 Soft Capsules 200mg?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIbuprofen (like other NSAIDs) should be used with caution in association with: corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4); anticoagulants: NSAIDs may increase the effects of anticoagulants such as warfarin (see section 4.4). It is advisable to monitor patients treated with coumarins; acetylsalicylic acid and other NSAIDs: these substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). The concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased undesirable effects. Experimental data suggest that ibuprofen may competitively inhibit low dose acetylsalicylic acid on platelet aggregation when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1). It is however advisable not to combine ibuprofen with aspirin or other NSAIDs; antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4); diuretics, ACE inhibitors and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of nephrotoxicity associated with NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Buscofen concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, this combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and periodically thereafter; lithium: concomitant administration of lithium and NSAIDs causes an increase in lithium levels in the blood due to reduced elimination, with the possibility of reaching the toxic threshold. If this combination is necessary, monitor lithium levels in order to adapt the lithium dosage during concomitant treatment with ibuprofen; methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and reduce its clearance, resulting in an increased risk of toxicity; aminoglycosides: NSAIDs may decrease the excretion of aminoglycosides; cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides; phenytoin: NSAIDs may lead to an increase in plasma concentrations of phenytoin; cholestyramine: concomitant administration of ibuprofen and cholestyramine may reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown; ciclosporin: increased risk of nephrotoxicity with NSAIDs; COX-2 inhibitors and other NSAIDs: concomitant use with other NSAIDs, including cyclooxygenase-2 selective inhibitors, should be avoided due to the potential additive effect (see section 4.4); herbal extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs; mifepristone: due to the antiprostaglandin properties of NSAIDs, a decrease in the efficacy of the medicinal product may theoretically occur. Limited evidence suggests that co-administration of NSAIDs on the day of prostaglandin administration does not adversely influence the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination; quinolone antibiotics: animal data indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions; sulfonylureas: NSAIDs may increase sulfonylureas. Rare cases of hypoglycaemia have been reported in patients treated with sulfonylureas who were taking ibuprofen; tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered with tacrolimus; zidovudine: increased risk of haematotoxicity in case of co-administration with NSAIDs. There is evidence of an increased risk of haemarthrosis and haematoma in HIV-infected haemophiliac patients receiving concomitant treatment with zidovudine and other NSAIDs; ritonavir: possible increase in the concentration of NSAIDs; probenecid: slows the excretion of NSAIDs with possible increase in their plasma concentrations; sulfinpyrazone: may delay the excretion of ibuprofen; CYP2C9 inhibitors: concomitant administration of ibuprofen and CYP2C9 inhibitors may increase exposure to ibuprofen (CYP2C9 substrate). In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)-ibuprofen by approximately 80% to 100% was observed. A reduction of the ibuprofen dose should be considered when strong CYP2C9 inhibitors are co-administered, particularly when high doses of ibuprofen are administered with voriconazole and fluconazole.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Buscofen 12 Soft Capsules 200 mg can cause side effects - What are the side effects of Buscofen 12 Soft Capsules 200mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe undesirable effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs. Gastrointestinal disorders: the most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal haemorrhage, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Gastrointestinal perforation with the use of ibuprofen has been observed rarely. After administration of Buscofen the following have been reported: nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, epigastric pain, heartburn, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Less frequently, gastritis has been observed. Pancreatitis has also been observed very rarely. Immune system disorders: hypersensitivity reactions have been reported following treatment with NSAIDs. These may consist of a) non-specific allergic reaction and anaphylaxis, b) respiratory tract reactions including asthma, including severe asthma, bronchospasm or dyspnoea or c) skin disorders including rashes of various types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). Cardiac and vascular disorders: Oedema and fatigue, hypertension and cardiac failure have been reported in association with NSAID treatment. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a modest increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Other adverse events reported less frequently and for which causality has not necessarily been established include: Blood and lymphatic system disorders: leukopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia. Psychiatric disorders: insomnia, anxiety, depression, confusional state, hallucinations. Nervous system disorders: headache, paraesthesia, dizziness, somnolence, optic neuritis. Infections and infestations: aseptic rhinitis and meningitis (especially in patients with pre-existing autoimmune disorders, such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). Respiratory, thoracic and mediastinal disorders: bronchospasm, dyspnoea, apnoea. Eye disorders: rare cases of ocular alteration resulting in visual disturbances, toxic optic neuropathy. Ear and labyrinth disorders: impaired hearing, tinnitus, vertigo. Hepatobiliary disorders: impaired liver function, liver failure, hepatitis and jaundice. Skin and subcutaneous tissue disorders: bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (very rare), photosensitivity reactions and drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) (frequency not known), acute generalized exanthematous pustulosis (AGEP) (frequency not known). Renal and urinary disorders: impaired renal function and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure. General disorders and administration site conditions: malaise, fatigue. Reporting of suspected adverse reactions Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Buscofen 12 Soft Capsules 200mg.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or embryo\/fetal development. Data from epidemiological studies suggest an increased risk of miscarriage, cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor during early pregnancy. The absolute risk of cardiac malformations increases from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, ibuprofen should not be given unless clearly necessary. If used by women attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be as low and as short as possible, respectively. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at the end of pregnancy, to: possible prolongation of bleeding time and antiaggregant effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, ibuprofen is contraindicated during the third trimester of pregnancy. Breastfeeding: in the few studies available to date, NSAIDs may be found in breast milk in very low concentrations. NSAIDs should, if possible, be avoided during breastfeeding. Fertility: The use of ibuprofen may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of fertility, discontinuation of ibuprofen should be considered.\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207822389363,"sku":"029396037","price":7.91,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-buscofen-12-capsule-molli-200mg-farmacia-dottor-tili-1213792773.jpg?v=1767112233"},{"product_id":"buscopan-40-compresse-rivestite-10-mg","title":"Buscopan 40 Coated Tablets 10 mg","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBuscopan\u003c\/span\u003e \u003cspan\u003eis a drug used to treat abdominal cramps and pain, especially those related to gastrointestinal and urinary tract disorders. The active ingredient,\u003c\/span\u003e \u003cspan\u003ebutylscopolamine bromide\u003c\/span\u003e \u003cspan\u003e, acts as an antispasmodic, relaxing the smooth muscles of the gastrointestinal and urinary tract, thus reducing pain and discomfort. Thanks to its localized action, Buscopan is effective in the treatment of intestinal spasms, colic and similar disorders\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eBuscopan is indicated for:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eSymptomatic treatment of abdominal cramps\u003c\/span\u003e \u003cspan\u003eand pain caused by gastrointestinal spasms.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eRelief of pain from renal and biliary colic\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eTreatment of spasms and pain related to urinary tract disorders\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eActive ingredients contained in Buscopan 40 Coated Tablets 10 mg - What is the active ingredient of Buscopan 40 Coated Tablets 10 mg?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eCoated tablets, one coated tablet contains: N-butyl hyoscine bromide 10 mg. Excipients: sucrose. Suppositories, one suppository contains: N-butyl hyoscine bromide 10 mg. For a full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Buscopan 40 Coated Tablets 10 mg - What does Buscopan 40 Coated Tablets 10 mg contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eCoated tablets; core: calcium hydrogen phosphate, maize starch, soluble starch, colloidal anhydrous silica, tartaric acid, stearic acid. Coating: povidone, sucrose, talc, gum arabic, titanium dioxide (E171), macrogol 6000, carnauba wax, white wax. Suppositories: solid semi-synthetic glycerides.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eTherapeutic indications Buscopan 40 Coated Tablets 10 mg - Why is Buscopan 40 Coated Tablets 10 mg used? What is it used for?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eSymptomatic treatment of spastic-painful manifestations of the gastrointestinal tract.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Buscopan 40 Coated Tablets 10 mg - When should Buscopan 40 Coated Tablets 10 mg not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients. Acute angle glaucoma. Prostatic hypertrophy or other causes of urinary retention. Pyloric stenosis and other conditions stenosing the gastrointestinal tract. Mechanical stenosis of the gastrointestinal tract. Paralytic or obstructive ileus. Megacolon. Ulcerative colitis. Reflux esophagitis. Intestinal atony in the elderly and debilitated subjects. Myasthenia gravis. Children under 6 years of age. In case of rare hereditary conditions of incompatibility with one of the excipients (see section 4.4 \"Special warnings and precautions for use\"), the use of the medicinal product is contraindicated.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Buscopan 40 Coated Tablets 10 mg - How to take Buscopan 40 Coated Tablets 10 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage: The following dosages are recommended for adults and children over 14 years of age. Coated tablets: 1-2 coated tablets 3 times a day. Suppositories: 1 suppository 3 times a day. Single doses can be increased according to the doctor's judgment. In pediatrics, in children aged between 6 and 14 years, the doctor's prescription must be followed exactly. Method of administration: The tablets must be swallowed whole with an adequate amount of water. Buscopan must not be taken daily on a regular basis or for prolonged periods without looking for the cause of the abdominal pain.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Buscopan 40 Coated Tablets 10 mg - How to store Buscopan 40 Coated Tablets 10 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eCoated tablets: This medicine does not require any special storage conditions. Suppositories: Do not store above 30 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWarnings Buscopan 40 Coated Tablets 10 mg - About Buscopan 40 Coated Tablets 10 mg it is important to know that:\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIf severe abdominal pain of unknown cause persists or worsens, or occurs with other symptoms such as fever, nausea, vomiting, changes in bowel movement, abdominal tenderness, decreased blood pressure, fainting, or blood in the stool, seek medical attention immediately. Anticholinergics should be used with caution in the elderly, in patients with autonomic nervous system disorders, cardiac tachyarrhythmias, arterial hypertension, congestive heart failure, hyperthyroidism, and in patients with liver and kidney disease. Because of the potential risk of complications related to excessive anticholinergic effect, caution should be exercised in patients subject to narrow-angle glaucoma as well as in patients susceptible to intestinal and urinary stasis and in those prone to tachyarrhythmias. Anticholinergics may prolong gastric emptying time and cause antral stasis. Due to the possibility that anticholinergics may reduce sweating, Buscopan should be administered with caution in patients with pyrexia. Treatment with high doses should not be stopped abruptly. Minor side effects can be controlled by appropriately reducing the dose; the appearance of important secondary manifestations requires the interruption of therapy. One 10 mg coated tablet contains 41.2 mg of sucrose equivalent to 247.2 mg per maximum recommended daily dose. Therefore, patients with rare hereditary problems of fructose intolerance should not take this medicine.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Buscopan 40 Coated Tablets 10 mg - Which medicines or foods can modify the effect of Buscopan 40 Coated Tablets 10 mg?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eanticholinergic drugs such as tri- and tetracyclic antidepressants, phenothiazines, butyrophenones, antihistamines, antipsychotics, quinidine, amantadine, diisopyramide and other anticholinergics (e.g. tiotropium, ipratropium and atropine-like compounds) may be accentuated by Buscopan. Concomitant treatment with dopamine antagonists, such as metoclopramide, may cause a reduction in the effect of both drugs on the gastrointestinal tract. Tachycardia induced by beta-adrenergic drugs may be accentuated by Buscopan. Do not consume alcohol during therapy. Since antacids may reduce the intestinal absorption of anticholinergics, these drugs should not be administered concomitantly.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eLike all medicines, Buscopan 40 Coated Tablets 10 mg can cause side effects - What are the side effects of Buscopan 40 Coated Tablets 10 mg?\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eMany of the listed adverse reactions can be attributed to the anticholinergic properties of Buscopan. The anticholinergic side effects of Buscopan are generally mild and self-limiting. Immune system disorders. Uncommon frequency: skin reactions, urticaria, pruritus; unknown frequency*: anaphylactic shock, anaphylactic reactions, dyspnoea, skin rash, erythema and other manifestations of hypersensitivity. * These adverse reactions have been observed in post-marketing experience. With a 95% probability, the frequency category is not greater than uncommon (3\/1368), but could be lower. A precise estimate of the frequency is not possible since these adverse reactions did not occur in 1368 patients in clinical trials. Cardiac disorders. Uncommon frequency: tachycardia. Gastrointestinal disorders. Uncommon frequency: dry mouth. Constipation has also been observed. Skin and subcutaneous tissue disorders. Uncommon: sweating disorders. Renal and urinary disorders. Rare: urinary retention. The following undesirable effects have also been observed. Eye disorders: mydriasis, accommodation disorders, increased ocular tone. Nervous system disorders: drowsiness. High doses may cause signs of central stimulation and more serious signs of interference with the nervous system, the state of consciousness and cardiorespiratory function. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Buscopan 40 Coated Tablets 10 mg.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThere are limited data from the use of hyoscine N-butylbromide in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). There is insufficient information on the excretion of Buscopan and its metabolites in human milk. As a precautionary measure, it is preferable to avoid the use of Buscopan during pregnancy and breastfeeding. No studies on the effects on human fertility have been performed (see section 5.3).\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207822454899,"sku":"006979088","price":17.01,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-buscopan-40-compresse-rivestite-10-mg-farmacia-dottor-tili-1213792764.jpg?v=1767125423"},{"product_id":"mag-2-orosolubile-20-bustine-2-25-g","title":"Mag 2 Orosolubile 20 Sachets 2.25 g","description":"\u003cp\u003e\u003cstrong\u003eMag 2 Orosolubile\u003c\/strong\u003e is a \u003cstrong\u003emagnesium\u003c\/strong\u003e -based food supplement formulated to combat magnesium deficiency states that can manifest themselves with tiredness, fatigue, muscle cramps or irritability. Magnesium is an essential mineral for the correct functioning of muscles, the nervous system and to reduce the feeling of tiredness and fatigue. The orosoluble sachets of Mag 2 offer a practical and fast method of intake, without the need for water.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Mag 2 Orosolubile 20 Sachets 2.25 g - What is the active ingredient in Mag 2 Orosolubile 20 Sachets 2.25 g?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eOne vial of oral solution contains, active ingredient: 1,500 g of magnesium pidolate (corresponding to 122 mg of Mg^++ ion). Excipients with known effects: sucrose, sodium methyl parahydroxybenzoate E219, sodium propyl parahydroxybenzoate E217, ethanol (contained in the orange flavour excipient). One single-dose sachet of oral solution contains, active ingredient: 1,500 g of magnesium pidolate (corresponding to 122 mg of Mg^++ ion). Excipients with known effects: sucrose, sodium methyl parahydroxybenzoate E219, sodium propyl parahydroxybenzoate E217, ethanol (contained in the orange flavour excipient). One sachet of powder for oral solution contains, active ingredient: 2,250 g of magnesium pidolate (corresponding to 184 mg of Mg^++ ion). Excipients with known effect: sucrose. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Mag 2 Orosolubile 20 Sachets 2.25 g - What does Mag 2 Orosolubile 20 Sachets 2.25 g contain?\u003c\/span\u003e\n\u003c\/h2\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eMag2 1.5 g\/10 ml oral solution: sucrose, orange flavouring (containing ethanol), sodium methyl parahydroxybenzoate E 219, sodium propyl parahydroxybenzoate E217, purified water. Mag2 2.25 g powder for oral solution: sodium saccharin, citric acid monohydrate, sucrose, lemon flavouring.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eDIRECTIONS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Mag 2 Orosolubile 20 Sachets 2.25 g - Why is Mag 2 Orosolubile 20 Sachets 2.25 g used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eMagnesium deficiency states.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eCONTRAINDICATIONS - SIDE EFFECTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Mag 2 Orosolubile 20 Sachets 2.25 g - When should Mag 2 Orosolubile 20 Sachets 2.25 g not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1; severe renal insufficiency (creatinine clearance less than 30 mL\/min); not to be administered to subjects undergoing digitalis therapy.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eDOSAGE\u003c\/span\u003e\n\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Mag 2 Orosolubile 20 Sachets 2.25 g - How do you take Mag 2 Orosolubile 20 Sachets 2.25 g?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eDosage, for adults only: 3 vials or 3 single-dose sachets of solution or 2 sachets of powder per day. Paediatric population: in children, the dosage may be established by a previously consulted doctor. Caution: use only for short periods of treatment. Instructions for use, Mag2 1.5 g\/10 ml oral solution: it is advisable to shake before use. To open the vial, twist the top and detach it. Take the contents of the vial as is or dilute it in water. Mag2 2.25 g powder for oral solution: dissolve the contents of one sachet in water.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eCONSERVATION\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Mag 2 Orosolubile 20 Sachets 2.25 g - How do you store Mag 2 Orosolubile 20 Sachets 2.25 g?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eOral solution: Store below 25 degrees C. Powder for oral solution: This medicine does not require any special storage conditions.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eWARNINGS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Mag 2 Orosolubile 20 Sachets 2.25 g - About Mag 2 Orosolubile 20 Sachets 2.25 g it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn case of concomitant calcium deficiency, magnesium deficiency should be corrected before administering supplemental calcium. In patients with moderate renal insufficiency, it is necessary to reduce the dosage and monitor renal function and magnesium levels, due to the risk associated with hypermagnesemia. It is advisable to consider the possibility that cardiovascular depression may occur during treatment. MAG2 oral solution contains sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Parahydroxybenzoates (sodium methyl parahydroxybenzoate E219 and sodium propyl parahydroxybenzoate E217): may cause allergic reactions (possibly delayed); sodium: this medicine contains less than 1 mmol sodium (23 mg) per vial or sachet, i.e. essentially \"sodium-free\"; ethanol: This medicine contains 18 mg of alcohol (ethanol) in each vial or sachet, which is equivalent to 1.8 mg\/ml. The amount in each dose of this medicine is equivalent to less than 0.2 ml of wine or 0.5 ml of beer. The small amount of alcohol in this medicine will not produce any relevant effects. MAG2 powder for oral solution contains sucrose: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Sodium: This medicine contains less than 1 mmol (23 mg) per dose, that is to say essentially 'sodium-free'.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Mag 2 Orosolubile 20 Sachets 2.25 g - Which medicines or foods can modify the effect of Mag 2 Orosolubile 20 Sachets 2.25 g?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eIn case of concomitant treatment with oral tetracyclines, the administration of MAG2 should be delayed by at least 3 hours. Quinolones should be administered at least 2 hours before or 6 hours after the administration of magnesium-containing products to avoid interference with their absorption. The concomitant administration of magnesium-containing products and cholecalciferol (vitamin D3) may lead to the onset of hypercalcemia. The concomitant use of preparations containing calcium or phosphate salts is not recommended because these products prevent intestinal absorption of magnesium. The simultaneous intake of magnesium-containing products with drugs that depress the Central Nervous System may potentiate the effects of magnesium on the CNS and should be carefully evaluated.\u003c\/span\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Mag 2 Orosolubile 20 Sachets 2.25 g can cause side effects - What are the side effects of Mag 2 Orosolubile 20 Sachets 2.25 g?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following convention has been used for the classification of undesirable effects: very common \u0026gt;= 1\/10; common \u0026gt;= 1\/100 and \u0026lt; 1\/10; uncommon \u0026gt;= 1\/1,000 and \u0026lt; 1\/100; rare \u0026gt;= 1\/10,000 and \u0026lt; 1\/1,000); very rare \u0026lt; 1\/10,000 and not known (frequency cannot be estimated from the available data). Gastrointestinal disorders. Frequency Not known: gastrointestinal disorders, diarrhoea, abdominal pain. Skin and subcutaneous tissue disorders. Frequency not known: skin reactions. Immune system disorders. Frequency not known: hypersensitivity. Exceptional cases of individual intolerance to magnesium have been reported, which can be treated with oral or parenteral antihistamines. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003cb\u003e \u003cbr\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Mag 2 Orosolubile 20 Sachets 2.25 g\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThere are limited data on the use of MAG2 in pregnant women. However, no conclusions can be drawn as to whether the use of MAG2 is safe during pregnancy. MAG2 can be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the fetus. Magnesium is considered compatible with breastfeeding.\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207823143027,"sku":"025519048","price":16.65,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/sanofi-spa-mag-2-orosolubile-20-bustine-2-25-g-farmacia-dottor-tili-1213792760.jpg?v=1767125746"},{"product_id":"mag-notte-24-bustine-orosolubili","title":"Mag Notte 24 Orosoluble Sachets","description":"\u003cp\u003e\u003cstrong\u003eMag Notte\u003c\/strong\u003e is a food supplement based on \u003cstrong\u003emagnesium\u003c\/strong\u003e , \u003cstrong\u003emelatonin\u003c\/strong\u003e and natural extracts such as \u003cstrong\u003ehawthorn\u003c\/strong\u003e and \u003cstrong\u003epassionflower\u003c\/strong\u003e , specially formulated to promote relaxation and improve the quality of sleep. This supplement helps reduce the time it takes to fall asleep and contributes to a deeper and more restful sleep. The orosoluble sachets are convenient to use and offer rapid intake, without the need for water.\u003c\/p\u003e\n\n\n\u003ch2\u003e Dosage and method of use\u003c\/h2\u003e\n\n\u003ch3\u003e How to take Mag Notte?\u003c\/h3\u003e\n\n\u003cp\u003e It is recommended to take \u003cstrong\u003e1 sachet\u003c\/strong\u003e per day, preferably in the evening, just before bedtime. The orosoluble sachets can be taken directly without water, making the intake practical and fast. It is recommended to follow a treatment cycle for at least 15-30 days to obtain the best results.\u003c\/p\u003e\n\n\n\u003ch2\u003e Ingredients\u003c\/h2\u003e\n\n\u003ch3\u003e What ingredients does Mag Notte contain?\u003c\/h3\u003e\n\n         \u003cp\u003eMag Notte contains a combination of natural and nutritional ingredients designed to promote relaxation and sleep:\n\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eMagnesium\u003c\/strong\u003e : essential for the normal functioning of the nervous system and to reduce tiredness.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eMelatonin\u003c\/strong\u003e : helps reduce the time it takes to fall asleep.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003ePassionflower\u003c\/strong\u003e : a natural extract with relaxing and anxiolytic properties.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eHawthorn\u003c\/strong\u003e : promotes relaxation and mental well-being, supporting sleep.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eVitamin B6\u003c\/strong\u003e : supports normal psychological function and contributes to the reduction of tiredness and fatigue.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Average analysis\u003c\/h2\u003e\n\n\u003cp\u003e Each sachet of Mag Notte contains:\n\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eMagnesium\u003c\/strong\u003e : 150 mg (40% NRV*)\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eMelatonin\u003c\/strong\u003e : 1 mg\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003ePassionflower dry extract\u003c\/strong\u003e : 100 mg\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eHawthorn dry extract\u003c\/strong\u003e : 100 mg\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eVitamin B6\u003c\/strong\u003e : 1.4 mg (100% VNR*)\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003e *Nutritional Reference Values ​​(NRV)\u003c\/p\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings of Mag Notte?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Do not exceed the recommended daily dose.\u003c\/li\u003e\n\n\u003cli\u003e Food supplements are not a substitute for a varied and balanced diet.\u003c\/li\u003e\n\n\u003cli\u003e Consult your doctor before use if you are pregnant, breastfeeding or have any medical conditions.\u003c\/li\u003e\n\n\u003cli\u003e Store in a cool, dry place, away from heat sources and direct light.\u003c\/li\u003e\n\n\u003cli\u003e Keep out of reach of children.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e Mag Notte is available in a pack of \u003cstrong\u003e24 orosoluble sachets\u003c\/strong\u003e . The sachets are practical to carry with you and allow for rapid intake without the need for water.\u003c\/p\u003e\n\n","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207823372403,"sku":"933194728","price":13.86,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/sanofi-spa-mag-notte-24-bustine-orosolubili-farmacia-dottor-tili-1213792756.jpg?v=1767125790"},{"product_id":"enterogermina-4-miliardi-5-ml-20-flaconcini","title":"Enterogermina 4 Billion\/5 Ml 20 Vials","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eEnterogermina 4 Billion\/5 Ml 20 Vials\u003c\/span\u003e \u003cspan\u003elactic ferments with probiotic action\u003c\/span\u003e \u003cspan\u003efor the\u003c\/span\u003e \u003cspan\u003etreatment and prophylaxis of intestinal dysbiosis.\u003c\/span\u003e \u003cspan\u003eHelps\u003c\/span\u003e \u003cspan\u003erestore intestinal balance\u003c\/span\u003e \u003cspan\u003ethanks to the spores of Bacillus clausii polyantibiotic resistant.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEnterogermina 4 Billion\/5 Ml 20 Vials is indicated for:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003ePrevention\u003c\/span\u003e \u003cspan\u003eand treatment of alterations in the normal balance of intestinal bacterial flora\u003c\/span\u003e \u003cspan\u003e(intestinal dysbiosis) and vitamin deficiencies in the body resulting from an imbalance in intestinal bacterial flora (endogenous dysvitaminosis).\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eAdjuvant therapy for the\u003c\/span\u003e \u003cspan\u003erestoration of the intestinal microbial flora\u003c\/span\u003e \u003cspan\u003e, altered during antibiotic or chemotherapy treatments.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n \u003cp role=\"presentation\" dir=\"ltr\"\u003e\u003cspan\u003eTreatment\u003c\/span\u003e \u003cspan\u003eof acute and chronic gastrointestinal diseases\u003c\/span\u003e \u003cspan\u003eof infants caused by intoxication or alterations in the normal balance of intestinal bacterial flora (intestinal dysmicrobism) or vitamin deficiencies in the body (dysvitaminosis).\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Enterogermina 4 Billion\/5 Ml 20 Vials - What is the active ingredient in Enterogermina 4 Billion\/5 Ml 20 Vials?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eOne vial contains, active substance: spores of polyantibiotic-resistant Bacillus clausii (strains SIN, O\/C, T, N\/R) 4 billion. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Enterogermina 4 Billion\/5 Ml 20 Vials - What does Enterogermina 4 Billion\/5 Ml 20 Vials contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eVials: purified water.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eTherapeutic indications Enterogermina 4 Billion\/5 Ml 20 Vials - Why is Enterogermina 4 Billion\/5 Ml 20 Vials used? What is it used for?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTreatment and prophylaxis of intestinal dysmicrobism and consequent endogenous dysvitaminosis. Adjuvant therapy for the restoration of intestinal microbial flora, altered during antibiotic or chemotherapy treatments. Acute and chronic gastro-intestinal disorders in infants, attributable to intoxications or intestinal dysmicrobism and dysvitaminosis.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Enterogermina 4 Billion\/5 Ml 20 Vials - When should Enterogermina 4 Billion\/5 Ml 20 Vials not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Enterogermina 4 Billion\/5 Ml 20 Vials - How is Enterogermina 4 Billion\/5 Ml 20 Vials taken?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eDosage. Adults: 1 vial per day. Infants and children: 1 vial per day. Method of administration: take the contents of the vial as is or diluted in water or other drinks (e.g. milk, tea, orange juice). This medicine is for oral use only. Do not inject or administer in any other way (see section 4.4).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Enterogermina 4 Billion\/5 Ml 20 Vials - How is Enterogermina 4 Billion\/5 Ml 20 Vials stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eStore below 30 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Enterogermina 4 Billion\/5 Ml 20 Vials - It is important to know that about Enterogermina 4 Billion\/5 Ml 20 Vials:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eSpecial warnings. Bacteremia\/sepsis: Cases of bacteremia, septicaemia and sepsis have been reported in immunocompromised or critically ill patients and in preterm infants since the introduction into the market. In some critically ill patients, the outcome was fatal. Enterogermina should be avoided in these groups of patients (see section 4.8). This medicinal product is for oral use only. Do not inject or administer by other routes. Incorrect use of the medicinal product has caused serious anaphylactic reactions such as anaphylactic shock. Precautions for use: during antibiotic therapy, it is advisable to administer the preparation in the interval between one and the other antibiotic administration. Any visible corpuscles in the vials of Enterogermina are due to aggregates of Bacillus clausii spores; therefore, they do not indicate an altered product. Shake the vial before use.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eInteractions Enterogermina 4 Billion\/5 Ml 20 Vials - Which medicines or foods can modify the effect of Enterogermina 4 Billion\/5 Ml 20 Vials?'\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNo interaction studies have been performed.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Enterogermina 4 Billion\/5 Ml 20 Vials can cause side effects - What are the side effects of Enterogermina 4 Billion\/5 Ml 20 Vials?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following undesirable effects have been observed during treatment with this medicinal product, classified according to the MedDRA organ class and frequency categories: very common (\u0026gt;=1\/10); common (\u0026gt;=1\/100, \u0026lt;1\/10); uncommon (\u0026gt;=1\/1,000, \u0026lt;1\/100); rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000); very rare \u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). Infections and infestations. Not known: bacteraemia, septicaemia and sepsis (in immunocompromised or severely ill patients) (see section 4.4). Skin and subcutaneous tissue disorders. Not known: hypersensitivity reactions, including rash, urticaria and angioedema. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Enterogermina 4 Billion\/5 Ml 20 Vials.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: There are no data available on the use of Enterogermina in pregnant women; therefore, it is not possible to draw conclusions on the safety of using Enterogermina during pregnancy. Enterogermina should be used during pregnancy only if the potential benefits for the mother outweigh the potential risks, including those for the fetus. Breastfeeding: There are no data available on the use of Enterogermina during breastfeeding regarding the composition of breast milk and the effects on the child. It is not possible to draw conclusions on the safety of using Enterogermina during breastfeeding. Enterogermina should be used during breastfeeding only if the potential benefits for the mother outweigh the potential risks, including those for the breastfed child. Fertility: There are no data available on the effect of Enterogermina on human fertility.\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207823798387,"sku":"013046089","price":25.02,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-enterogermina-4-miliardi-5-ml-20-flaconcini-farmacia-dottor-tili-1213792750.webp?v=1767125928"},{"product_id":"enterogermina-4-miliardi-5-ml-10-flaconcini","title":"Enterogermina 4 Billion\/5 Ml 10 Vials","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eEnterogermina 4 Billion\/5 Ml 10 Vials\u003c\/span\u003e \u003cspan\u003elactic ferments with probiotic action\u003c\/span\u003e \u003cspan\u003efor the\u003c\/span\u003e \u003cspan\u003etreatment and prophylaxis of intestinal dysbiosis.\u003c\/span\u003e \u003cspan\u003eHelps\u003c\/span\u003e \u003cspan\u003erestore intestinal balance\u003c\/span\u003e \u003cspan\u003ethanks to the spores of Bacillus clausii polyantibiotic resistant.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEnterogermina 4 Billion\/5 Ml 10 Vials is indicated for:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003ePrevention\u003c\/span\u003e \u003cspan\u003eand treatment of alterations in the normal balance of intestinal bacterial flora\u003c\/span\u003e \u003cspan\u003e(intestinal dysbiosis) and vitamin deficiencies in the body resulting from an imbalance in intestinal bacterial flora (endogenous dysvitaminosis).\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eAdjuvant therapy for the\u003c\/span\u003e \u003cspan\u003erestoration of the intestinal microbial flora\u003c\/span\u003e \u003cspan\u003e, altered during antibiotic or chemotherapy treatments.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n \u003cp role=\"presentation\" dir=\"ltr\"\u003e\u003cspan\u003eTreatment\u003c\/span\u003e \u003cspan\u003eof acute and chronic gastrointestinal diseases\u003c\/span\u003e \u003cspan\u003eof infants caused by intoxication or alterations in the normal balance of intestinal bacterial flora (intestinal dysmicrobism) or vitamin deficiencies in the body (dysvitaminosis).\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Enterogermina 4 Billion\/5 Ml 10 Vials - What is the active ingredient of Enterogermina 4 Billion\/5 Ml 10 Vials?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eOne vial contains, active substance: spores of polyantibiotic-resistant Bacillus clausii (strains SIN, O\/C, T, N\/R) 4 billion. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Enterogermina 4 Billion\/5 Ml 10 Vials - What does Enterogermina 4 Billion\/5 Ml 10 Vials contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eVials: purified water.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eTherapeutic indications Enterogermina 4 Billion\/5 Ml 10 Vials - Why is Enterogermina 4 Billion\/5 Ml 10 Vials used? What is it used for?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTreatment and prophylaxis of intestinal dysmicrobism and consequent endogenous dysvitaminosis. Adjuvant therapy for the restoration of intestinal microbial flora, altered during antibiotic or chemotherapy treatments. Acute and chronic gastro-intestinal disorders in infants, attributable to intoxications or intestinal dysmicrobism and dysvitaminosis.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Enterogermina 4 Billion\/5 Ml 10 Vials - When should Enterogermina 4 Billion\/5 Ml 10 Vials not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Enterogermina 4 Billion\/5 Ml 10 Vials - How is Enterogermina 4 Billion\/5 Ml 10 Vials taken?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eDosage. Adults: 1 vial per day. Infants and children: 1 vial per day. Method of administration: take the contents of the vial as is or diluted in water or other drinks (e.g. milk, tea, orange juice). This medicine is for oral use only. Do not inject or administer in any other way (see section 4.4).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Enterogermina 4 Billion\/5 Ml 10 Vials - How is Enterogermina 4 Billion\/5 Ml 10 Vials stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eStore below 30 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Enterogermina 4 Billion\/5 Ml 10 Vials - About Enterogermina 4 Billion\/5 Ml 10 Vials it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eSpecial warnings. Bacteremia\/sepsis: Cases of bacteremia, septicaemia and sepsis have been reported in immunocompromised or critically ill patients and in preterm infants since the introduction into the market. In some critically ill patients, the outcome was fatal. Enterogermina should be avoided in these groups of patients (see section 4.8). This medicinal product is for oral use only. Do not inject or administer by other routes. Incorrect use of the medicinal product has caused serious anaphylactic reactions such as anaphylactic shock. Precautions for use: during antibiotic therapy, it is advisable to administer the preparation in the interval between one and the other antibiotic administration. Any visible corpuscles in the vials of Enterogermina are due to aggregates of Bacillus clausii spores; therefore, they do not indicate an altered product. Shake the vial before use.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eInteractions Enterogermina 4 Billion\/5 Ml 10 Vials - Which medicines or foods can modify the effect of Enterogermina 4 Billion\/5 Ml 10 Vials?'\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNo interaction studies have been performed.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Enterogermina 4 Billion\/5 Ml 10 Vials can cause side effects - What are the side effects of Enterogermina 4 Billion\/5 Ml 10 Vials?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following undesirable effects have been observed during treatment with this medicinal product, classified according to the MedDRA organ class and frequency categories: very common (\u0026gt;=1\/10); common (\u0026gt;=1\/100, \u0026lt;1\/10); uncommon (\u0026gt;=1\/1,000, \u0026lt;1\/100); rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000); very rare \u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). Infections and infestations. Not known: bacteraemia, septicaemia and sepsis (in immunocompromised or severely ill patients) (see section 4.4). Skin and subcutaneous tissue disorders. Not known: hypersensitivity reactions, including rash, urticaria and angioedema. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Enterogermina 4 Billion\/5 Ml 10 Vials.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: There are no data available on the use of Enterogermina in pregnant women; therefore, it is not possible to draw conclusions on the safety of using Enterogermina during pregnancy. Enterogermina should be used during pregnancy only if the potential benefits for the mother outweigh the potential risks, including those for the fetus. Breastfeeding: There are no data available on the use of Enterogermina during breastfeeding regarding the composition of breast milk and the effects on the child. It is not possible to draw conclusions on the safety of using Enterogermina during breastfeeding. Enterogermina should be used during breastfeeding only if the potential benefits for the mother outweigh the potential risks, including those for the breastfed child. Fertility: There are no data available on the effect of Enterogermina on human fertility.\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207823831155,"sku":"013046077","price":9.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-enterogermina-4-miliardi-5-ml-10-flaconcini-farmacia-dottor-tili-1213792746.webp?v=1767125908"},{"product_id":"maalox-plus-30-compresse-masticabili","title":"Maalox plus 30 chewable tablets","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMaalox Plus 30 Chewable Tablets is a medicine indicated for the\u003c\/span\u003e \u003cspan\u003esymptomatic treatment of heartburn or stomach pain,\u003c\/span\u003e \u003cspan\u003edue to\u003c\/span\u003e \u003cspan\u003ehyperacidity and gastroesophageal reflux.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eMaalox Plus reduces the amount of acid in the stomach and excess intestinal gas. Maalox Plus is also indicated for the\u003c\/span\u003e \u003cspan\u003etreatment of peptic ulcers\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003cspan\u003e\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients in Maalox plus 30 chewable tablets - What is the active ingredient in Maalox plus 30 chewable tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e100 ml of suspension contains the active substances: magnesium hydroxide 3.65 g, aluminium hydroxide 3.25 g, dimethicone 0.50 g. Excipient(s) with known effect: methyl parahydroxybenzoate, propyl parahydroxybenzoate, ethanol, invert sugar, sucrose, sulphur dioxide (E 220), sorbitol (E420) 4.48 g\/ 100 ml (see section 4.4). For the full list of excipients, see section 6.1. One tablet contains the active substances: magnesium hydroxide 200 mg, aluminium oxide, hydrate 200 mg, dimethicone 25 mg. Excipient(s) with known effect: glucose, sucrose, sorbitol (E420) 45 mg per tablet (see section 4.4). For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Maalox plus 30 chewable tablets - What does Maalox plus 30 chewable tablets contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eMaalox Plus 3.65% + 3.25% + 0.5% oral suspension: methylcellulose, methyl parahydroxybenzoate, propyl parahydroxybenzoate, carmellose, hydroxypropylcellulose, citric acid, sodium saccharin, sorbitol (E420) non-crystallising liquid, lemon flavouring (containing ethanol), Swiss cream flavouring (containing ethanol, invert sugar, sucrose, sulphur dioxide (E 220)), purified water. Maalox Plus 200 mg +200 mg + 25 mg chewable tablets: corn starch, citric acid, pregelatinized starch, glucose, mannitol, sucrose, sorbitol (E420), non-crystallizing liquid sorbitol, talc, magnesium stearate, sodium saccharin, lemon flavouring, Swiss cream flavouring, E 172.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Maalox plus 30 chewable tablets - Why is Maalox plus 30 chewable tablets used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eSymptomatic treatment of hyperacidity (including burning and pain) including in cases of esophagitis, and of hyperacidity when accompanied by dyspepsia. Symptomatic treatment of gastrointestinal bloating when accompanied by hyperacidity.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Maalox plus 30 chewable tablets - When should Maalox plus 30 chewable tablets not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1; patients with porphyria; severe forms of renal insufficiency (creatinine clearance less than 30 mL\/min); generally contraindicated in pediatric age; state of cachexia.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Maalox plus 30 chewable tablets - How to take Maalox plus 30 chewable tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eMaalox Plus 3.65% + 3.25% + 0.5% oral suspension. Dosage: do not exceed the maximum doses indicated unless prescribed by a doctor. Ingest 2-4 teaspoons (10-20 ml) 4 times a day, 20-60 minutes after meals and before going to bed. Method of administration: shake well before use. It can be diluted in water or milk. Maalox Plus 200 mg + 200 mg + 25 mg chewable tablets. Dosage: do not exceed the maximum doses indicated unless prescribed by a doctor. 2-4 tablets 4 times a day, chewed or sucked well, 20-60 minutes after meals and before going to bed. Method of administration: the tablets must be chewed or sucked well. Their intake can be followed by ingestion of water or milk. Paediatric population: administration of the medicine in paediatric age is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Maalox plus 30 chewable tablets - How to store Maalox plus 30 chewable tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eOral suspension: Do not store below 4 degrees C. Bottle: Keep the bottle tightly closed. Chewable tablets: Store below 25 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Maalox plus 30 chewable tablets - About Maalox plus 30 chewable tablets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eAluminium hydroxide may cause constipation and an overdose of magnesium salts may cause intestinal hypermotility; high doses of this medicine may cause or worsen intestinal obstruction and ileus in patients at higher risk, such as those with renal impairment, with underlying constipation, with impaired intestinal motility, in children (0 to 24 months), or in the elderly. Aluminium hydroxide is not well absorbed from the gastrointestinal tract, and systemic effects are therefore rare in patients with normal renal function. However, excessive doses or long-term use, or even normal doses in patients on low-phosphorus diets or in children (0 to 24 months), may lead to phosphate excretion (due to an aluminium-phosphate bond) accompanied by increased bone resorption and hypercalciuria with risk of osteomalacia. It is advisable to consult a doctor in case of long-term use or in patients at risk of hypophosphatemia. In patients with renal impairment, plasma levels of aluminum and magnesium tend to increase, causing hyperaluminemia and hypermagnesemia, respectively. In these patients, long-term exposure to high doses of aluminum and magnesium salts may lead to encephalopathy, dementia, microcytic anemia or worsening of dialysis-induced osteomalacia. In the presence of mild and moderate forms of renal insufficiency, it is advisable to take the product under medical supervision. Prolonged use of antacids in patients with mild and moderate forms of renal insufficiency should be avoided. The administration of this medicinal product is contraindicated in subjects suffering from severe forms of renal insufficiency (see section 4.3). Aluminum hydroxide may not be safe in patients with porphyria undergoing haemodialysis (see section 4.3). Maalox Plus, due to its composition, does not tend to modify bowel habits. However, in some particularly sensitive subjects and for high doses, an acceleration of intestinal transit may occur. Maalox Plus 3.65% + 3.25% + 0.5% oral suspension contains parahydroxybenzoates: may cause allergic reactions (possibly delayed); 448 mg of sorbitol (E420) in 10 ml (2 teaspoons). Patients with hereditary fructose intolerance should not be given this medicine; ethanol: this medicine contains 9.5 mg of ethanol in 10 ml (2 teaspoons). 10 ml of this medicine is equivalent to 0.2 ml of beer or 0.1 ml of wine. The small amount of alcohol in this medicine will not produce any relevant effects; sucrose and invert sugar: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine; sulphur dioxide (E 220): may rarely cause severe hypersensitivity reactions and bronchospasm; less than 1 mmol sodium (23 mg) per dose, i.e. essentially \"sodium-free\". Maalox Plus 200 mg + 200 mg + 25 mg chewable tablets contain: 45 mg disorbitol, per tablet. The concomitant administration of medicinal products containing sorbitol (or fructose) and the daily intake of sorbitol (or fructose) with the diet should be taken into account. The sorbitol content in oral medicinal products may alter the bioavailability of other concomitant oral medicinal products. Patients with hereditary fructose intolerance should not be given this medicine. Approximately 500 mg glucose, per tablet: to be taken into account in patients with diabetes mellitus, if more than 10 tablets per day are taken; patients with rare problems of glucose-galactose malabsorption should not take this medicine. Sucrose: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Less than 1 mmol sodium (23 mg) per tablet, i.e. essentially \"sodium-free\". Paediatric population: In young children, the use of magnesium hydroxide may lead to hypermagnesaemia, particularly if they have renal impairment or dehydration.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eMaalox plus 30 chewable tablets interactions - Which medicines or foods can modify the effect of Maalox plus 30 chewable tablets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eSince Al and Mg salts reduce the gastrointestinal absorption of tetracyclines, it is recommended to avoid taking Maalox Plus during oral tetracycline therapy. The use of aluminum-containing antacids may reduce the absorption of drugs, particularly H2-antagonists, atenolol, bisphosphonates, cefdinir, cefpodoxime, chloroquine, tetracyclines, dasatinib monohydrate, diflunisal, digoxin, dexamethasone, eltrombopag olamine, elvitegravir, ethambutol, fluoroquinolones, glucocorticoids, indomethacin, iron salts, isoniazid, ketoconazole, levothyroxine, lincosamides, metoprolol, nilotinib, phenothiazine neuroleptics, penicillamine, propranolol, raltegravir potassium, rilpivirine, riociguat, rosuvastatin, sodium fluoride and antiviral treatments in combination with tenofovir alafenamide fumarate\/emtricitabine\/ bictegravir sodium. Polystyrene sulfonate (Kayexalate): Caution is advised when the medicinal product is taken together with polystyrene sulfonate (Kayexalate) due to the potential risk of reduced efficacy of the resin in binding potassium, metabolic alkalosis in patients with renal impairment (reported with aluminium hydroxide and magnesium hydroxide), and intestinal obstruction (reported with aluminium hydroxide). Aluminium hydroxide and citrates may cause hypoalbuminaemia, especially in patients with renal impairment. The combination with integrase inhibitors (dolutegravir, raltegravir, bictegravir) and Maalox Plus should be avoided (refer to their respective SmPCs for dose recommendations). Since the use of magnesium hydroxide causes alkalinization of urine, increased excretion of salicylates has been observed when administered concomitantly. As a precaution, allow at least 2 hours (4 hours for fluoroquinolones) to elapse between taking any oral medication and Maalox Plus. Concomitant use of quinidine may increase serum quinidine levels and lead to quinidine overdose. Concomitant use of aluminum hydroxide and citrates may increase aluminum levels, particularly in patients with renal insufficiency. Alkalinization of urine following administration of magnesium hydroxide may alter the excretion of some drugs; therefore, increased excretion of salicylates has been observed.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Maalox plus 30 chewable tablets can cause side effects - What are the side effects of Maalox plus 30 chewable tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe frequency of adverse reactions listed below is defined using the following conventions: common (\u0026gt;=1\/100, \u0026lt;1\/10); uncommon (\u0026gt;=1\/1,000, \u0026lt;1\/100); rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000); very rare (\u0026lt;1\/10,000); not known (cannot be estimated from the available data). Immune system disorders. Frequency not known (cannot be estimated from the available data): angioedema, anaphylactic reactions, hypersensitivity reactions, urticaria, pruritus. Gastrointestinal disorders. Uncommon: diarrhoea or constipation (see section 4.4); frequency not known: abdominal pain. Metabolism and nutrition disorders. Very rare: hypermagnesaemia, including observations after prolonged administration to patients with renal impairment; frequency not known: hypoalbuminaemia, hypophosphatemia, during prolonged use or at high doses or even at normal doses of the medicinal product in patients with low phosphorus diets or in children (0 to 24 months), which may cause increased bone resorption, hypercalciuria, osteomalacia (see section 4.4). Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Maalox plus 30 chewable tablets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThere are no data on the use of Maalox Plus in pregnant women. It is not possible to establish whether or not the use of Maalox Plus during pregnancy is safe. Pregnancy: the medicine should be used only in case of need, under the direct supervision of a doctor, after evaluating the expected benefit for the mother in relation to the possible risk for the fetus or the infant. Breastfeeding: due to the limited maternal absorption when taken according to the indicated dosage regimen (see section 4.2), aluminium hydroxide and its combinations with magnesium salts are considered compatible with breastfeeding.\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207823863923,"sku":"020702080","price":9.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/sanofi-spa-maalox-plus-30-compresse-masticabili-farmacia-dottor-tili-1213792745.webp?v=1767125889"},{"product_id":"fexallegra-10-compresse-rivestite-120-mg","title":"Fexallegra 10 Coated Tablets 120 mg","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFexallegra 10 Coated Tablets 120 mg\u003c\/span\u003e \u003cspan\u003eis a drug indicated for the symptomatic treatment of seasonal and chronic allergies, such as allergic rhinitis and urticaria. The active ingredient, fexofenadine hydrochloride, belongs to the category of second-generation antihistamines, known for their ability to effectively reduce allergic symptoms without causing marked drowsiness. Thanks to its 120 mg formulation, Fexallegra acts quickly, with a prolonged effect that lasts up to 24 hours, improving the quality of life during allergy seasons.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eFexallegra is indicated for:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eSymptomatic treatment of\u003c\/span\u003e \u003cspan\u003eseasonal allergic rhinitis\u003c\/span\u003e \u003cspan\u003ein adults and adolescents aged 12 years and above.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eChronic idiopathic urticaria\u003c\/span\u003e \u003cspan\u003e, reducing symptoms such as itching and the appearance of wheals.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eActive ingredients contained in Fexallegra 10 Coated Tablets 120 mg - What is the active ingredient of Fexallegra 10 Coated Tablets 120 mg?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eOne tablet contains: active substance: 120 mg fexofenadine hydrochloride, equivalent to 112 mg fexofenadine. For a full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Fexallegra 10 Coated Tablets 120 mg - What does Fexallegra 10 Coated Tablets 120 mg contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTablet core: microcrystalline cellulose; pregelatinized maize starch; croscarmellose sodium; magnesium stearate. Film coating: hypromellose; povidone K30; titanium dioxide (E171); colloidal anhydrous silica; macrogol 400; red iron oxide (E172), yellow iron oxide (E172).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Fexallegra 10 Coated Tablets 120 mg - Why is Fexallegra 10 Coated Tablets 120 mg used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFexallegra is indicated in adults and children aged 12 years and above for the symptomatic treatment of allergic rhinitis.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Fexallegra 10 Coated Tablets 120 mg - When should Fexallegra 10 Coated Tablets 120 mg not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThe medicinal product is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Fexallegra 10 Coated Tablets 120 mg - How to take Fexallegra 10 Coated Tablets 120 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage. Adults: The recommended dose of fexofenadine hydrochloride for adults is 120 mg once daily, before meals. Fexofenadine is a pharmacologically active metabolite of terfenadine. Paediatric population. Children aged 12 years and above: The recommended dose of fexofenadine hydrochloride for children aged 12 years and above is 120 mg once daily, before meals. Children under 12 years of age: The efficacy and safety of fexofenadine hydrochloride 120 mg have not been studied in children under 12 years of age. In children aged 6 to 11 years: fexofenadine hydrochloride 30 mg tablets is the appropriate formulation for administration and dosing in this population. Special populations: Studies performed in groups of patients at risk (elderly, patients with renal or hepatic insufficiency) indicate that it is not necessary to adjust the dose of fexofenadine hydrochloride in these patients.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Fexallegra 10 Coated Tablets 120 mg - How to store Fexallegra 10 Coated Tablets 120 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicinal product does not require any special storage conditions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Fexallegra 10 Coated Tablets 120 mg - About Fexallegra 10 Coated Tablets 120 mg it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eData in elderly subjects and in patients with impaired renal or hepatic function are limited. Fexofenadine hydrochloride should be administered with caution to these groups of subjects (see section 4.2). Patients with pre-existing or existing cardiovascular disease should be informed that antihistamines, as a class of medicinal products, have been associated with adverse reactions such as tachycardia and palpitations (see section 4.8). Fexallegra contains sodium: this medicinal product contains less than 1 mmol sodium (23 mg) per tablet, i.e. essentially \"sodium-free\".\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Fexallegra 10 Coated Tablets 120 mg - Which medicines or foods can modify the effect of Fexallegra 10 Coated Tablets 120 mg?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFexofenadine does not undergo hepatic biotransformation and therefore does not interact with other medicinal products at the level of hepatic mechanisms. Fexofenadine is a substrate of P-glycoprotein (P-gp) and organic anion transporting polypeptide (OATP). Concomitant use of fexofenadine with inhibitors or inducers of P-gp may influence the exposure to fexofenadine; co-administration of fexofenadine hydrochloride with the P-gp inhibitors, erythromycin or ketoconazole has been found to increase the plasma levels of fexofenadine by 2-3 fold. These alterations were not accompanied by any effect on the QT interval and were not associated with any increase in adverse reactions compared to those observed with the same medicinal products administered alone. A clinical drug-drug interaction study demonstrated that co-administration of apalutamide (a weak P-gp inducer) and a single oral dose of 30 mg fexofenadine resulted in a 30% decrease in fexofenadine AUC. No interaction was observed between fexofenadine and omeprazole. However, administration of an antacid containing aluminium and magnesium hydroxide 15 minutes prior to administration of fexofenadine hydrochloride resulted in a reduction in bioavailability, most likely due to binding in the gastrointestinal tract. A 2-hour interval between administration of fexofenadine hydrochloride and antacids containing aluminium and magnesium hydroxide is recommended.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Fexallegra 10 Coated Tablets 120 mg can cause side effects - What are the side effects of Fexallegra 10 Coated Tablets 120 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following frequency category has been used, where applicable: very common (\u0026gt;= 1\/10); common (\u0026gt;= 1\/100 and \u0026lt; 1\/10); uncommon (\u0026gt;= 1\/1,000 and \u0026lt; 1\/100); rare (\u0026gt;= 1\/10,000 and \u0026lt; 1\/1,000); very rare (\u0026lt; 1\/10,000) and not known (frequency cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. In adults, the following undesirable effects have been reported in clinical trials with an incidence similar to that observed with placebo. Nervous system disorders. Common: headache, somnolence, dizziness. Gastrointestinal disorders. Common: nausea. Systemic disorders and administration site conditions. Uncommon: fatigue. In adults, the following undesirable effects have been reported in post-marketing surveillance. The frequency with which they occur is not known (cannot be estimated from the available data). Immune system disorders: hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnoea, hot flushes and systemic anaphylaxis. Psychiatric disorders: insomnia, nervousness, sleep disturbances or nightmares\/excessive dreaming (paroniria). Cardiac disorders: tachycardia, palpitations. Gastrointestinal disorders: diarrhoea. Skin and subcutaneous tissue disorders: rash, urticaria and pruritus. Eye disorders: Not known: blurred vision. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Fexallegra 10 Coated Tablets 120 mg.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: There are no adequate data from the use of fexofenadine hydrochloride in pregnant women. Limited animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal\/foetal development, parturition or postnatal development (see section 5.3). Fexofenadine hydrochloride should not be used during pregnancy unless clearly necessary. Breastfeeding: There are no data on the concentration in breast milk after administration of fexofenadine hydrochloride. However, when terfenadine was administered to nursing mothers, fexofenadine was found to pass into breast milk. Therefore, the use of fexofenadine hydrochloride is not recommended during breastfeeding. Fertility: There are no data on the consumption of fexofenadine hydrochloride on human fertility. In mice, treatment with fexofenadine hydrochloride showed no effect on fertility (see section 5.3).\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207824584819,"sku":"042554042","price":12.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/sanofi-spa-fexallegra-10-compresse-rivestite-120-mg-farmacia-dottor-tili-1213792731.jpg?v=1767126850"},{"product_id":"enterogermina-gonfiore-probiotici-10-bustine-bipartite","title":"Enterogermina Swelling Probiotics 10 Bipartite Sachets","description":"\u003cp\u003eEnterogermina Gonfiore Probiotici 10 Bipartite Sachets \u003cstrong\u003elactic ferments with probiotic action\u003c\/strong\u003e with a specific formulation based on \u003cstrong\u003eenzymes, probiotics and plant extracts\u003c\/strong\u003e . The action of probiotics \u003cstrong\u003epromotes the balance of the intestinal bacterial flora\u003c\/strong\u003e . Digestive enzymes are protein molecules present in all living organisms, including the human body. They play a fundamental role in the digestion of food, because \u003cstrong\u003ethey accelerate and catalyze chemical reactions\u003c\/strong\u003e . Plant extracts (mint leaves and coriander fruits) help digestive functions and \u003cstrong\u003eregular gastrointestinal motility\u003c\/strong\u003e , promoting the \u003cstrong\u003eelimination of gas\u003c\/strong\u003e at the origin of abdominal swelling.\u003c\/p\u003e\n\n\u003cp\u003e Enterogermina gonfia is a \u003cstrong\u003egluten-free and lactose-free\u003c\/strong\u003e product.\u003c\/p\u003e\n\n\u003cp\u003e Enterogermina Gonfiore works thanks to its triple action:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eRebalances the intestinal bacterial flora\u003c\/strong\u003e thanks to the administration of probiotics;\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eReduces bacterial fermentation\u003c\/strong\u003e ;\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eIt helps intestinal motility\u003c\/strong\u003e to expel gas accumulated inside the stomach.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003e Enterogermina Gonfiore Probiotici 10 Bipartite Sachets is presented in the format of double sachets to be taken together in half a glass of water. The first group of sachets contains:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eProbiotics\u003c\/strong\u003e , such as Bifidobacterium Animalis subsp. Lactis and Lactobacillius acidophilus, which perform the function of rebalancing the intestinal flora highly compromised by various factors.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003e In the other group of sachets there are:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eFOS\u003c\/strong\u003e (fructooligosaccharides), prebiotics essential for the development and nourishment of intestinal bacteria;\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDry extract of mint leaves\u003c\/strong\u003e , highly appreciated for their spasmolytic and anti-flatulence properties, essential for restored gastrointestinal motility;\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eDry coriander extract\u003c\/strong\u003e , which works by reducing the symptoms of aerophagia;\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eα-galactosidase\u003c\/strong\u003e , a digestive enzyme that prevents the accumulation of intestinal gas. \u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\n\u003cdiv align=\"justify\"\u003e\n\n\u003ch3 data-mce-fragment=\"1\"\u003e Dosage and method of use Enterogermina Gonfiore Probiotics 10 Bipartite Sachets\u003c\/h3\u003e\n\n Cut both sachets of Enterogermina Gonfiore along the dotted line and drop the contents into half a glass of water. Stir to dissolve the powder. Drink the resulting suspension preferably before the main meal. \u003c\/div\u003e\n\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\n\u003ch3 align=\"justify\"\u003eActive ingredients and Excipients Enterogermina Gonfiore Probiotics 10 Bipartite Sachets\u003c\/h3\u003e\n\n\u003cdiv align=\"justify\"\u003e Average analysis per daily dose (1 paired sachet)\u003cbr\u003e\u003cbr\u003e Bifidobacterium animalis subsp. Lactis (BB-12) 2 billion UFC\u003cbr\u003e\u003cbr\u003e Lactobacillus acidophilus (LA-5) 1 billion CFU\u003cbr\u003e\u003cbr\u003e Fructo-oligosaccharides 1,750 mg\u003cbr\u003e\u003cbr\u003e Dry extract of mint leaves 200 mg\u003cbr\u003e\u003cbr\u003e Coriander fruit es 50 mg\u003cbr\u003e\u003cbr\u003e Fermented maltodextrin 40 mg\u003cbr\u003e\u003cbr\u003e Alpha-galactosidase 20 mg\u003c\/div\u003e\n\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\n\u003cdiv align=\"justify\"\u003e \n\u003cstrong\u003eProbiotic ingredients\u003c\/strong\u003e : fructo-oligosaccharides, fructose, Bifidobacterium Animalis subsp. Lactis (BB-12) DSM 15954 (maltodextrin), Lactobacillus Acidophilus (LA-5) DMS 13241 (maltodextrin), anti-caking agent: silicon dioxide, flavouring.\u003c\/div\u003e\n\n\u003cdiv align=\"justify\"\u003e\n\n\u003cbr\u003e \u003cstrong\u003eIngredients: enzymes\u003c\/strong\u003e : fructose, fructo-oligosaccharides, Mint (Mentha piperita L., maltodextrin, silicon dioxide) leaves dry extract 0.5% rosmarinic acid, Coriander (Coriandrum sativum L., corn maltodextrin) fruit dry extract, Enzymix – fermented maltodextrins (rice dextrins), flavourings, alpha-galactosidase from Aspergillus niger (maltodextrins) 1% thousands of GAL, anti-caking agent: silicon dioxide, acidifier: citric acid. \u003c\/div\u003e\n\n\u003cdiv align=\"justify\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\n\u003cdiv align=\"justify\"\u003e\n\u003cbr\u003e\n\n\u003c\/div\u003e\n\n\u003cdiv align=\"justify\"\u003e\n\n\u003ch3\u003e Special warnings Enterogermina Gonfiore Probiotics 10 Bipartite Sachets\u003c\/h3\u003e\n\n \u003cp\u003eProbiotics and enzymes are very delicate elements that must be stored with the utmost care to preserve their functionality. This is why Enterogermina gonfia is composed of coupled sachets that allow the separate storage of the two nutrients until the moment of intake.\u003cbr\u003e Do not exceed the recommended dose. Food supplements should not be considered as a substitute for a varied and balanced diet and a healthy lifestyle. Keep out of reach of children under 3 years of age.\u003c\/p\u003e\n\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch3\u003e Expiry and storage Enterogermina Gonfiore Probiotics 10 Bipartite Sachets\u003c\/h3\u003e\n\n Store the product at a temperature below 30°C. The expiry date refers to the product correctly stored in an intact package. Do not dispose of in the environment.\u003cbr\u003e\n\n\u003c\/div\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40207824650355,"sku":"935190393","price":15.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/sanofi-spa-enterogermina-gonfiore-probiotici-10-bustine-bipartite-farmacia-dottor-tili-1213792713.jpg?v=1767126929"},{"product_id":"enterogermina-2-miliardi-5-ml-20-flaconcini","title":"Enterogermina 2 Billion\/5 Ml 20 Vials","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eEnterogermina 2 Billion\/5 Ml 20 Vials\u003c\/span\u003e \u003cspan\u003elactic ferments with probiotic action\u003c\/span\u003e \u003cspan\u003efor the\u003c\/span\u003e \u003cspan\u003etreatment and prophylaxis of intestinal dysbiosis.\u003c\/span\u003e \u003cspan\u003eHelps\u003c\/span\u003e \u003cspan\u003erestore intestinal balance\u003c\/span\u003e \u003cspan\u003ethanks to the spores of Bacillus clausii polyantibiotic resistant.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEnterogermina 2 Billion\/5 Ml 20 Vials is indicated for:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003ePrevention\u003c\/span\u003e \u003cspan\u003eand treatment of alterations in the normal balance of intestinal bacterial flora\u003c\/span\u003e \u003cspan\u003e(intestinal dysbiosis) and vitamin deficiencies in the body resulting from an imbalance in intestinal bacterial flora (endogenous dysvitaminosis).\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n\u003cp role=\"presentation\" dir=\"ltr\"\u003e \u003cspan\u003eAdjuvant therapy for the\u003c\/span\u003e \u003cspan\u003erestoration of the intestinal microbial flora\u003c\/span\u003e \u003cspan\u003e, altered during antibiotic or chemotherapy treatments.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli aria-level=\"1\" dir=\"ltr\"\u003e\n\n \u003cp role=\"presentation\" dir=\"ltr\"\u003e\u003cspan\u003eTreatment\u003c\/span\u003e \u003cspan\u003eof acute and chronic gastrointestinal diseases\u003c\/span\u003e \u003cspan\u003eof infants caused by intoxication or alterations in the normal balance of intestinal bacterial flora (intestinal dysmicrobism) or vitamin deficiencies in the body (dysvitaminosis).\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003e\"\u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Enterogermina 2 Billion\/5 Ml 20 Vials - What is the active ingredient of Enterogermina 2 Billion\/5 Ml 20 Vials?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eOne vial contains, active substance: spores of polyantibiotic-resistant Bacillus clausii (strains SIN, O\/C, T, N\/R) 2 billion. One hard capsule contains, active substance: spores of polyantibiotic-resistant Bacillus clausii (strains SIN, O\/C, T, N\/R) 2 billion. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Enterogermina 2 Billion\/5 Ml 20 Vials - What does Enterogermina 2 Billion\/5 Ml 20 Vials contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eVials: purified water. Capsules: microcrystalline cellulose, magnesium stearate, gelatin, titanium dioxide (E171), purified water.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Enterogermina 2 Billion\/5 Ml 20 Vials - Why is Enterogermina 2 Billion\/5 Ml 20 Vials used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTreatment and prophylaxis of intestinal dysmicrobism and consequent endogenous dysvitaminosis. Adjuvant therapy for the restoration of intestinal microbial flora, altered during antibiotic or chemotherapy treatments. Acute and chronic gastro-intestinal disorders in infants, attributable to intoxications or intestinal dysmicrobism and dysvitaminosis.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Enterogermina 2 Billion\/5 Ml 20 Vials - When should Enterogermina 2 Billion\/5 Ml 20 Vials not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Enterogermina 2 Billion\/5 Ml 20 Vials - How is Enterogermina 2 Billion\/5 Ml 20 Vials taken?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eAdults: 2-3 vials per day or 2-3 capsules per day. Children: 1-2 vials per day or 1-2 capsules per day. Infants: 1-2 vials per day. Vials: administration at regular intervals. Take the contents of the vial as is or diluted in water or other drinks (e.g. milk, tea, orange juice). Capsules: swallow with a sip of water or other drinks. Especially in younger children, in case of difficulty swallowing the hard capsules, it is advisable to use the oral suspension. This medicine is for oral use only. Do not inject or administer in any other way (see section 4.4).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eStorage Enterogermina 2 Billion\/5 Ml 20 Vials - How is Enterogermina 2 Billion\/5 Ml 20 Vials stored?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eStore below 30 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Enterogermina 2 Billion\/5 Ml 20 Vials - About Enterogermina 2 Billion\/5 Ml 20 Vials it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eSpecial warnings. Bacteremia\/sepsis: Cases of bacteremia, septicaemia and sepsis have been reported in immunocompromised or critically ill patients and in preterm infants since the introduction into the market. In some critically ill patients, the outcome was fatal. Enterogermina should be avoided in these groups of patients (see section 4.8). This medicinal product is for oral use only. Do not inject or administer by other routes. Incorrect use of the medicinal product has caused serious anaphylactic reactions such as anaphylactic shock. Precautions for use: during antibiotic therapy, it is advisable to administer the preparation in the interval between one and the other antibiotic administration. Any visible corpuscles in the vials of Enterogermina are due to aggregates of Bacillus clausii spores; therefore, they do not indicate an altered product. Shake the vial before use.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eInteractions Enterogermina 2 Billion\/5 Ml 20 Vials - Which medicines or foods can modify the effect of Enterogermina 2 Billion\/5 Ml 20 Vials?'\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNo interaction studies have been performed.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Enterogermina 2 Billion\/5 Ml 20 Vials can cause side effects - What are the side effects of Enterogermina 2 Billion\/5 Ml 20 Vials?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following undesirable effects have been observed during treatment with this medicinal product, classified according to the MedDRA organ class and frequency categories: very common (\u0026gt;=1\/10); common (\u0026gt;=1\/100, \u0026lt;1\/10); uncommon (\u0026gt;=1\/1,000, \u0026lt;1\/100); rare (\u0026gt;=1\/10,000, \u0026lt;1\/1,000); very rare \u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). Infections and infestations. Not known: bacteraemia, septicaemia and sepsis (in immunocompromised or severely ill patients) (see section 4.4). Skin and subcutaneous tissue disorders. Not known: hypersensitivity reactions, including rash, urticaria and angioedema. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Enterogermina 2 Billion\/5 Ml 20 Vials.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: There are no data available on the use of Enterogermina in pregnant women; therefore, it is not possible to draw conclusions on the safety of using Enterogermina during pregnancy. Enterogermina should be used during pregnancy only if the potential benefits for the mother outweigh the potential risks, including those for the fetus. Breastfeeding: There are no data available on the use of Enterogermina during breastfeeding regarding the composition of breast milk and the effects on the child. It is not possible to draw conclusions on the safety of using Enterogermina during breastfeeding. Enterogermina should be used during breastfeeding only if the potential benefits for the mother outweigh the potential risks, including those for the breastfed child. Fertility: There are no data available on the effect of Enterogermina on human fertility.\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":40733625090163,"sku":"013046040","price":20.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-enterogermina-2-miliardi-5-ml-20-flaconcini-farmacia-dottor-tili-1213792519.jpg?v=1767131110"},{"product_id":"bisolvon-linctus-sciroppo-mucolitico-tosse-grassa-250-ml-4-mg-5-ml","title":"Bisolvon Linctus Mucolytic Syrup for Fatty Cough 250 ml 4 mg\/5 ml","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBisolvon Linctus is a Bromexine-based syrup with\u003c\/span\u003e \u003cspan\u003emucolytic action\u003c\/span\u003e \u003cspan\u003esuitable for adults, adolescents and children. Useful in case of acute and chronic respiratory diseases, with\u003c\/span\u003e \u003cspan\u003ecough and production of phlegm\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eBisolvon Linctus concentrates at the level of bronchial and pulmonary tissue, where phlegm is present. Here it acts with its triple effect:\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eIt thins mucus deposits in the airways.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eIt helps to expectorate and eliminate phlegm.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e \u003cspan\u003eCalms coughs.\u003c\/span\u003e\u003c\/p\u003e\n\n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eBisolvon Linctus syrup\u003c\/span\u003e \u003cspan\u003econtains neither sucrose nor fructose\u003c\/span\u003e \u003cspan\u003eand can be administered to diabetics.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml - What is the active ingredient of Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e5 ml of syrup contain; active ingredient: bromexine hydrochloride 4 mg (equivalent to bromexine 3.65 mg). Excipient with known effect: maltitol. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml - What does Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eBenzoic acid, liquid maltitol, sucralose, chocolate flavor, cherry flavor, levomenthol, purified water.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml - Why is Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eBisolvon is indicated in the treatment of secretion disorders in acute and chronic respiratory diseases.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml - When should Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance or to any of the excipients. The drug is contraindicated in children under 2 years of age. In case of hereditary conditions that may be incompatible with one of the excipients (see 4.4). There are no absolute contraindications, but in patients with gastroduodenal ulcer, its use is recommended after consulting the doctor. Contraindicated during breastfeeding (see paragraph 4.6).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml - How do you take Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following dosages are recommended unless otherwise prescribed by your doctor. Adults: 5 - 10 ml 3 times a day. In adults, at the beginning of treatment, it may be necessary to increase the total daily dose up to 48 mg divided into three times. Children over 2 years of age: 2.5 - 5 ml 3 times a day. It is recommended to take the medicine after meals. The syrup can be administered to diabetics and children over 2 years of age, it does not contain fructose or sucrose. Do not exceed the recommended doses. To measure the appropriate dose, use the measuring cup included in the package (with marks at 1.25 ml equal to 1 mg of bromexine hydrochloride, 2.5 equal to 2 mg of bromexine hydrochloride and 5 ml equal to 4 mg of bromexine hydrochloride).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml - How is Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis medicinal product does not require any special storage conditions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml - About Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eTreatment with Bisolvon leads to increased bronchial secretion (this promotes expectoration). Do not use for prolonged treatment. In the treatment of acute respiratory conditions, consult your doctor if symptoms do not improve or worsen during therapy. Cases of serious skin reactions such as erythema multiforme, Stevens-Johnson syndrome (SJS)\/toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP) have been reported in association with the administration of bromhexine hydrochloride. If symptoms or signs of progressive skin rash (sometimes associated with blisters or mucosal lesions) are present, treatment with bromhexine hydrochloride should be stopped immediately and a doctor should be consulted. Most of these reactions could be explained by the severity of underlying diseases or other drugs taken at the same time. In addition, in the early stages of Stevens-Johnson syndrome or toxic epidermal necrolysis (TEN), patients may initially experience non-specific flu-like symptoms, such as fever, chills, rhinitis, cough and sore throat. Because of these misleading symptoms, symptomatic treatment with cough and cold therapy may be initiated. Mucolytics may induce bronchial obstruction in children under 2 years of age. In fact, the ability to drain bronchial mucus is limited in this age group, due to the physiological characteristics of the airways. They should therefore not be used in children under 2 years of age (see section 4.3). The medicinal product contains liquid maltitol: the maximum recommended daily dose of Bisolvon 4 mg\/5 ml contains 15 g of maltitol (30 g in case of increased daily dose in adults at the start of treatment), patients with rare problems of fructose intolerance should not take this medicinal product. This medicine may have a mild laxative effect.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml - Which medicines or foods can modify the effect of Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg\/5 ml?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNo clinically relevant interactions with other medicinal products have been reported.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Bisolvon Linctus Mucolytic Syrup for Chesty Cough 250 ml 4 mg\/5 ml can cause side effects - What are the side effects of Bisolvon Linctus Mucolytic Syrup for Chesty Cough 250 ml 4 mg\/5 ml?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFrequencies are defined using the following convention: very common: \u0026gt;= 1\/10; common: \u0026gt;= 1\/100, \u0026lt; 1\/10; uncommon: \u0026gt;= 1\/1,000, \u0026lt; 1\/100; rare: \u0026gt;= 1\/10,000, \u0026lt; 1\/1,000; very rare: \u0026lt; 1\/10,000; not known: frequency cannot be estimated from the available data. Immune system disorders: Rare: hypersensitivity reactions; not known: anaphylactic reactions, including anaphylactic shock, angioedema and pruritus. Respiratory, thoracic and mediastinal disorders: Not known: bronchospasm. Gastrointestinal disorders: Uncommon: nausea, vomiting, diarrhoea and upper abdominal pain. Skin and subcutaneous tissue disorders: Rare: rash, urticaria; not known: serious cutaneous adverse reactions (including erythema multiforme, Stevens-Johnson syndrome\/toxic epidermal necrolysis, and acute generalized exanthematous pustulosis). Reporting of suspected adverse reactions. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Bisolvon Linctus Mucolytic Syrup for Chesty Cough 250 ml 4 mg\/5 ml\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eNo studies have been conducted to investigate the effects on human fertility. Based on preclinical experience there is no indication of possible effects on fertility following the use of bromhexine. There are limited data on the use of bromhexine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Bisolvon during pregnancy. It is not known whether bromhexine and its metabolites pass into human milk. Available pharmacodynamic and toxicological data in animals have shown excretion of bromhexine and its metabolites in breast milk. A risk to breast-fed children cannot be excluded. Bisolvon should not be used during breast-feeding.\u003c\/span\u003e\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":46492461924679,"sku":"021004041","price":12.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/sanofi-spa-bisolvon-linctus-sciroppo-mucolitico-tosse-grassa-250-ml-4-mg-5-ml-farmacia-dottor-tili-1213792491.jpg?v=1767112510"},{"product_id":"buscofenact-400mg-12-capsule-molli","title":"Buscofenact 400mg 12 soft capsules","description":"Buscofenact 400mg 12 softgels is a medicine formulated for the \u003cstrong\u003eshort-term symptomatic treatment\u003c\/strong\u003e of mild to moderate pain, such as headache, toothache and menstrual pain, as well as fever and pain associated with the common cold. Each softgel contains \u003cstrong\u003e400 mg of ibuprofen\u003c\/strong\u003e , an active ingredient known for its anti-inflammatory and analgesic properties. This medicine is indicated for adults and adolescents with a body weight of more than 40 kg (aged 12 years and over). The softgels are designed for quick and easy oral intake, ensuring rapid relief from symptoms. Ibuprofen works by inhibiting the synthesis of prostaglandins, chemicals in the body that cause inflammation and pain. \u003cstrong\u003eBuscofenact\u003c\/strong\u003e is an effective choice for those seeking quick and temporary relief from painful and feverish symptoms.\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e  \u003ch3\u003eActive ingredients contained in Buscofenact 400mg 12 soft capsules - What is the active ingredient of Buscofenact 400mg 12 soft capsules?\u003c\/h3\u003e One soft capsule contains 400 mg ibuprofen. \u003cu\u003eExcipients with known effect\u003c\/u\u003e : Sorbitol 95.94 mg\/capsule (see section 4.4). For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Buscofenact 400mg 12 soft capsules - What does Buscofenact 400mg 12 soft capsules contain?\u003c\/h3\u003e \u003ci\u003e\u003cu\u003eCapsule contents:\u003c\/u\u003e\u003c\/i\u003e Macrogol 600 Potassium hydroxide Purified water \u003ci\u003e\u003cu\u003eCapsule shell\u003c\/u\u003e\u003c\/i\u003e \u003cu\u003e:\u003c\/u\u003e Gelatin Liquid sorbitol Purified water \u003ci\u003e\u003cu\u003ePrinting ink\u003c\/u\u003e\u003c\/i\u003e Ingredients of Opacode WB black NS-78-17821: Black iron oxide (E172) Propylene glycol (E1520) Hypromellose 6cP\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Buscofenact 400mg 12 soft capsules - Why is Buscofenact 400mg 12 soft capsules used? What is it used for? \u003c\/h3\u003eShort-term symptomatic treatment of: - mild to moderate pain such as headache, toothache and period pain; - fever and pain associated with the common cold. BuscofenAct is indicated in adults and adolescents with a body weight of more than 40 kg (aged 12 years and over).\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Buscofenact 400mg 12 soft capsules - When should Buscofenact 400mg 12 soft capsules not be used? \u003c\/h3\u003eBuscofenAct soft capsules is contraindicated in case of: - hypersensitivity to ibuprofen or to any of the excipients listed in section 6.1; - history of hypersensitivity (e.g. bronchospasm, asthma, rhinitis, angioedema or urticaria) associated with the intake of acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs (NSAIDs); - haematological disorders of unknown origin; - history of recurrent or active peptic ulcer\/haemorrhage (two or more distinct episodes, with proven ulceration or bleeding); - history of gastrointestinal bleeding or perforation, related to previous therapy with NSAIDs; - cerebrovascular haemorrhage or other bleeding episodes; - severe heart failure (NYHA class IV) (see also section 4.4); - severe hepatic insufficiency or severe renal insufficiency (see also section 4.4); - patients in the third trimester of pregnancy (see section 4.6); - adolescents with body weight below 40 kg and children under 12 years of age; - patients with severe dehydration (due to vomiting, diarrhoea or insufficient fluid intake).\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Buscofenact 400mg 12 soft capsules - How to take Buscofenact 400mg 12 soft capsules? \u003c\/h3\u003e\n\u003cb\u003e\u003cu\u003eDosage\u003c\/u\u003e\u003c\/b\u003e Adults and adolescents with body weight \u0026gt; 40 kg (aged 12 years and over): Initial dose of 400 mg ibuprofen. If necessary, an additional dose of 400 mg ibuprofen may be taken. The interval between doses should be based on the symptoms observed and the maximum recommended daily dose, and should not be less than 6 hours. Do not take more than 1200 mg ibuprofen in 24 hours. For short-term treatment only. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). If BuscofenAct soft capsules must be taken in adults for more than 3 days in case of fever or for more than 4 days for the treatment of pain or if symptoms worsen, the patient is advised to consult a doctor. It is recommended that people with gastric disorders take it on a full stomach. If taken shortly after eating, the onset of the effect of BuscofenAct may be delayed. If this occurs, do not take BuscofenAct more than recommended in section 4.2 (dosage) or until the correct dose interval has elapsed. \u003cb\u003eSpecial patient populations\u003c\/b\u003e \u003cu\u003eElderly\u003c\/u\u003e No special dosage adjustments are required. Due to possible undesirable effects (see section 4.4), elderly patients should be carefully monitored. \u003cu\u003eRenal impairment\u003c\/u\u003e No special dosage adjustments are required in patients with mild or moderate renal impairment (for patients with severe renal impairment, see section 4.3). \u003cu\u003eHepatic impairment (see section 5.2)\u003c\/u\u003e No special dosage adjustments are required in patients with mild or moderate liver impairment (for patients with severe liver dysfunction, see section 4.3). \u003ci\u003ePaediatric population\u003c\/i\u003e BuscofenAct is contraindicated in adolescents with a body weight below 40 kg and in children under 12 years of age due to the high content of active ingredient (see section 4.3). If the use of the medicinal product is necessary for more than 3 days in adolescents, or in case of worsening of symptoms, a doctor should be consulted. \u003cb\u003e\u003cu\u003eMethod of administration\u003c\/u\u003e\u003c\/b\u003e For oral use. The soft capsules should not be chewed.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Buscofenact 400mg 12 soft capsules - How to store Buscofenact 400mg 12 soft capsules?\u003c\/h3\u003e This medicine does not require any special storage temperatures.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Buscofenact 400mg 12 soft capsules - About Buscofenact 400mg 12 soft capsules it is important to know that: \u003c\/h3\u003eUndesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see sections below on gastrointestinal and cardiovascular risks). Caution is required in patients with certain clinical conditions, which may be exacerbated: - patients with systemic lupus erythematosus and various connective tissue diseases have an increased risk of developing aseptic meningitis (see section 4.8); - congenital disorder of porphyrin metabolism (e.g. acute intermittent porphyria); - gastrointestinal diseases and chronic inflammatory bowel diseases (ulcerative colitis, Crohn's disease) (see section 4.8); - hypertension and\/or cardiac impairment as renal function may deteriorate (see sections 4.3 and 4.8); - renal impairment (see sections 4.3 and 4.8); - hepatic dysfunction (see sections 4.3 and 4.8); - immediately after major surgery; - in patients with allergic reactions to other substances, since there is an increased risk of hypersensitivity reactions also following the use of BuscofenAct; - in patients suffering from hay fever, nasal polyps or chronic obstructive airway diseases since there is an increased risk of allergic reactions. These reactions may present as asthma attacks (so-called analgesic asthma), Quincke's oedema or urticaria. \u003cu\u003eGastrointestinal effects\u003c\/u\u003e The use of BuscofenAct soft capsules in combination with other NSAIDs, including cyclooxygenase-2 selective inhibitors, increases the risk of adverse reactions and should be avoided. \u003ci\u003eElderly\u003c\/i\u003e Elderly subjects have a higher frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). \u003ci\u003eGastrointestinal bleeding, ulceration or perforation\u003c\/i\u003e Gastrointestinal bleeding, ulceration or perforation, sometimes fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of GI events. If GI bleeding or ulceration occurs in patients receiving ibuprofen, the treatment should be withdrawn. The risk of GI bleeding, ulceration or perforation is increased with higher NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in elderly patients. These patients should start treatment on the lowest dose available. Concomitant therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients receiving concomitant low dose aspirin or other drugs likely to increase gastrointestinal risk (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) especially in the initial stages of treatment. Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5). NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as their condition may be exacerbated (see section 4.8). \u003cu\u003eSevere skin reactions\u003c\/u\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy; in fact, in the majority of cases, the reaction occurs within the first month of treatment. Acute generalized exanthematous pustulosis (AGEP) has been reported in relation to medicinal products containing ibuprofen. Administration of BuscofenAct soft capsules should be suspended at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Exceptionally, chickenpox may be the cause of serious skin infections and soft tissue complications. It is recommended not to use BuscofenAct soft capsules during chickenpox. \u003cu\u003eMasking of symptoms of underlying infections\u003c\/u\u003e BuscofenAct soft capsules may mask the symptoms of infection, which may delay initiation of adequate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When BuscofenAct soft capsules are administered for the relief of infection-related fever or pain, monitoring for infection is recommended. In non-hospital settings, the patient should seek medical advice if symptoms persist or worsen. \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e Caution is advised (discuss with your doctor or pharmacist) before initiating treatment in patients with a history of hypertension and\/or heart failure, since fluid retention, hypertension and oedema have been reported in association with NSAID therapy. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg daily), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg daily) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg daily) should be avoided. Careful consideration should also be exercised before initiating long-term treatment in patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), especially if high doses (2400 mg daily) of ibuprofen are required. \u003cu\u003eOther warnings and precautions\u003c\/u\u003e Severe acute hypersensitivity reactions (e.g. anaphylactic shock) have been observed very rarely. At the first signs of a hypersensitivity reaction following intake\/administration of BuscofenAct soft capsules, therapy should be discontinued. The required medical measures should be carried out by experienced personnel. Ibuprofen, the active ingredient of BuscofenAct soft capsules, may temporarily inhibit platelet function (platelet aggregation). Therefore, patients with platelet disorders should be carefully monitored. In case of prolonged treatment with ibuprofen, liver and kidney parameters as well as the blood picture should be checked regularly. Prolonged use of any analgesic for headache may worsen it. If this situation occurs or is suspected, the doctor should be consulted and treatment should be discontinued. The diagnosis of medication-overuse headache (MOH) should be suspected in patients with frequent or daily headaches despite (or because of) the regular use of headache medications. In general, the habitual use of analgesics, particularly the combination of different analgesic active ingredients, may lead to permanent kidney damage with the risk of renal failure (analgesic nephropathy). This risk may be increased under physical exertion associated with salt loss and dehydration. Therefore, this should be avoided. In case of concomitant alcohol consumption during the use of NSAIDs, adverse events related to the active ingredient, especially those affecting the gastrointestinal tract or the central nervous system, may increase. \u003cu\u003ePaediatric population\u003c\/u\u003e There is a risk of impaired renal function in dehydrated adolescents. Sorbitol BuscofenAct contains 95.94 mg of sorbitol in each capsule. Patients with hereditary fructose intolerance, a rare genetic disease, should not take this medicine.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Buscofenact 400mg 12 soft capsules - Which medicines or foods can modify the effect of Buscofenact 400mg 12 soft capsules?\u003c\/h3\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eConcomitant use of ibuprofen with:\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003ePossible effects:\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Other NSAIDs, including salicylates\u003c\/td\u003e\n\u003ctd\u003e Concomitant administration of several NSAIDs may increase the risk of gastrointestinal bleeding and ulcers due to a synergistic effect. Therefore, concomitant use of ibuprofen with other NSAIDs should be avoided (see section 4.4).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Digoxin\u003c\/td\u003e\n\u003ctd\u003e Concomitant use of BuscofenAct soft capsules with drugs containing digoxin may increase serum digoxin levels. Usually, if digoxin is used correctly (for a maximum of 4 days) it is not necessary to monitor serum digoxin levels.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Corticosteroids\u003c\/td\u003e\n\u003ctd\u003e Corticosteroids may increase the risk of adverse reactions, particularly of the gastrointestinal tract (gastrointestinal bleeding or ulceration) (see section 4.4).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e  \u003ctd\u003eAntiplatelet agents\u003c\/td\u003e\n\u003ctd\u003e Increased risk of gastrointestinal bleeding (see section 4.4).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Acetylsalicylic acid\u003c\/td\u003e\n\u003ctd\u003e Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Anticoagulants\u003c\/td\u003e  \u003ctd\u003eNSAIDs may increase the effects of anticoagulants, such as warfarin (see section 4.4).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Phenytoin\u003c\/td\u003e\n\u003ctd\u003e Concomitant use of BuscofenAct and phenytoin preparations may increase serum phenytoin levels. Usually, if used correctly (for a maximum of 4 days) it is not necessary to monitor serum phenytoin levels.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Selective serotonin reuptake inhibitors (SSRIs)\u003c\/td\u003e\n\u003ctd\u003e Increased risk of gastrointestinal bleeding (see section 4.4).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Lithium\u003c\/td\u003e\n\u003ctd\u003e Concomitant use of BuscofenAct with lithium preparations may increase serum lithium levels. Usually, if used correctly (for a maximum of 4 days) it is not necessary to monitor serum lithium levels.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Probenecid and sulfinpyrazone\u003c\/td\u003e\n\u003ctd\u003e Drugs containing probenecid and sulfinpyrazone may delay the elimination of ibuprofen.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Diuretics, ACE inhibitors, beta-blockers and angiotensin II antagonists\u003c\/td\u003e  \u003ctd\u003eNSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (especially dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor, a beta-blocker or angiotensin II antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, these combinations should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function at the start of concomitant therapy and periodically thereafter.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Potassium-sparing diuretics\u003c\/td\u003e\n\u003ctd\u003e Concomitant administration of BuscofenAct and potassium-sparing diuretics may lead to hyperkalemia.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Methotrexate\u003c\/td\u003e  \u003ctd\u003eBuscofenAct administered within 24 hours before or after taking methotrexate may increase its concentrations and therefore its toxicity.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Cyclosporin\u003c\/td\u003e\n\u003ctd\u003e The risk of renal damage induced by ciclosporin may be increased by concomitant use of some NSAIDs. This effect cannot be excluded in case of concomitant intake of ciclosporin and ibuprofen.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Tacrolimus\u003c\/td\u003e\n\u003ctd\u003e The risk of nephrotoxicity increases with concomitant administration of ibuprofen and tacrolimus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Zidovudine\u003c\/td\u003e\n\u003ctd\u003e When ibuprofen and zidovudine are administered concomitantly, there is evidence of an increased risk of haemarthroses and haematomas in HIV-positive haemophiliacs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Sulfonylureas\u003c\/td\u003e  \u003ctd\u003eClinical studies have shown that there are interactions between nonsteroidal anti-inflammatory drugs and antidiabetic drugs (sulfonylureas). Although no interactions between ibuprofen and sulfonylureas have been described so far, in case of concomitant use of these two drugs it is advisable to monitor blood sugar levels.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Quinolone antibiotics\u003c\/td\u003e\n\u003ctd\u003e Animal studies indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of developing seizures.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e CYP2C9 inhibitors\u003c\/td\u003e  \u003ctd\u003eConcomitant administration of ibuprofen and CYP2C9 inhibitors may increase the exposure to ibuprofen (CYP2C9 substrate). In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)-ibuprofen by approximately 80% to 100% was observed. Consideration should be given to reducing the ibuprofen dose when strong CYP2C9 inhibitors are co-administered, particularly when high doses of ibuprofen are administered with voriconazole and fluconazole.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Mifepristone\u003c\/td\u003e\n\u003ctd\u003e NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs may reduce the effect of mifepristone.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Buscofenact 400mg 12 soft capsules can cause side effects - What are the side effects of Buscofenact 400mg 12 soft capsules? \u003c\/h3\u003eThe list of undesirable effects reported below refers to all undesirable effects that have been reported during treatment with ibuprofen, including those observed during long-term and high-dose treatment in patients with rheumatic diseases. The reported frequencies, which occur with an incidence greater than very rare cases, refer to the short-term use of daily doses of up to a maximum of 1200 mg of ibuprofen for the oral dosage form and a maximum of 1800 mg for suppositories. It should be taken into account that the following undesirable effects are essentially dose-dependent and vary from individual to individual. The most commonly observed undesirable events are gastrointestinal in nature. Peptic ulcer, perforation or gastrointestinal haemorrhage, even with fatal outcome, may occur, especially in the elderly (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, worsening of colitis and Crohn's disease have been reported following administration (see section 4.4). Gastritis has been observed less frequently. The risk of gastrointestinal bleeding depends on the dose and duration of treatment. Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg daily), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Patients should be advised to stop taking BuscofenAct immediately and to consult their doctor if a serious adverse reaction occurs. Adverse reactions are listed below by system organ class and frequency, using the following categories: Very common (≥1\/10) Common (≥1\/100, \u0026lt;1\/10) Uncommon (≥1\/1000, \u0026lt;1\/100) Rare (≥1\/10,000, \u0026lt;1\/1000) Very rare (\u0026lt;1\/10,000) Not known (cannot be estimated from the available data)  \u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\u003ctd\u003e In association with the use of nonsteroidal anti-inflammatory drugs, worsening of infectious inflammation (e.g. development of necrotizing fasciitis) has been observed. This is probably associated with the mechanism of action of nonsteroidal anti-inflammatory drugs. Symptoms of aseptic meningitis with stiff neck, headache, nausea, vomiting, fever or blurred consciousness have been observed during treatment with ibuprofen. Patients with autoimmune diseases (SLE, mixed connective tissue disease) appear to be predisposed.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003ePathologies of the haemolymphopoietic system\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e  \u003ctd\u003eHematopoietic disorders (anemia, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis). The first signs may be: fever, sore throat, superficial sores in the mouth, flu-like symptoms, severe tiredness, nosebleeds and skin bleeding. In long-term therapy, blood counts should be monitored regularly.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e \u003cb\u003eImmune system disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\u003ctd\u003e Hypersensitivity reactions with skin rashes, itching, asthma attacks (with possible drop in blood pressure).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\u003ctd\u003e Severe generalized hypersensitivity reactions, signs of which may include facial edema, swelling of the tongue, swelling of the larynx with constriction of the airways, respiratory distress, tachycardia, drop in blood pressure, up to life-threatening shock. If any of these symptoms occur, and this can happen even on the first use, immediate medical attention is required.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003ePsychiatric disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e  \u003ctd\u003ePsychotic reactions, depression.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eNervous system disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\u003ctd\u003e Central nervous system disorders, such as headache, dizziness, insomnia, agitation, irritability or tiredness.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eEye pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\u003ctd\u003e Visual disturbances.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eEar and labyrinth pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Rare\u003c\/td\u003e\n\u003ctd\u003e Tinnitus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eHeart disease\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\u003ctd\u003e Palpitations, heart failure, myocardial infarction.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eVascular pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\u003ctd\u003e Arterial hypertension, vasculitis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"3\"\u003e \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Common\u003c\/td\u003e\n\u003ctd\u003e Gastrointestinal disorders, such as heartburn, abdominal pain, nausea, dyspepsia, vomiting, flatulence, diarrhea, constipation, slight gastrointestinal blood loss which in exceptional cases leads to anemia.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\u003ctd\u003e Gastrointestinal ulcer with potential for haemorrhage and perforation. Ulcerative stomatitis, worsening of colitis and Crohn's disease (see section 4.4), gastritis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e  \u003ctd\u003eEsophagitis, pancreatitis, diaphragmatic intestinal stenosis formation. If severe pain in the upper abdomen is felt or if melena or hematemesis occurs, it is recommended to inform the doctor immediately and stop taking the medicine.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eHepatobiliary pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\u003ctd\u003e Liver dysfunction, liver damage, especially in case of prolonged therapy, liver failure, acute hepatitis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"3\"\u003e \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\u003ctd\u003e Various skin rashes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\u003ctd\u003e Bullous reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome), alopecia. In exceptional cases, serious skin and soft tissue infections may occur during chickenpox infection (see also \"Infections and infestations\").\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Not known\u003c\/td\u003e\n\u003ctd\u003e Acute generalized exanthematous pustulosis (AGEP). Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). Photosensitivity reactions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e  \u003ctd rowspan=\"2\"\u003e\u003cb\u003eKidney and urinary disorders\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e Rare\u003c\/td\u003e\n\u003ctd\u003e Rarely, damage to the kidney tissue (papillary necrosis) and high concentrations of uric acid in the blood may also be observed.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\u003ctd\u003e Formation of edema, especially in patients with arterial hypertension or renal insufficiency, nephrotic syndrome, interstitial nephritis, which may be accompanied by acute renal failure. Renal function should be monitored regularly.\u003c\/td\u003e\n\u003c\/tr\u003e  \u003c\/table\u003eIf necessary, patients should be adequately informed to stop treatment with BuscofenAct and consult a doctor immediately if any of the following conditions occur: - severe gastro-intestinal disturbances, heartburn or abdominal pain; - haematemesis; - melaena or blood in the urine; - skin reactions, such as itchy rashes; - respiratory distress and\/or swelling of the face or larynx; - fatigue associated with loss of appetite; - sore throat, associated with aphthous ulcers, fatigue and fever; - severe nosebleeds and skin bleeding; - abnormal tiredness associated with reduced urine output; - swelling of the feet or legs; - chest pain; - visual disturbances. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eOVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Buscofenact 400mg 12 soft capsules Overdose - What are the risks of Buscofenact 400mg 12 soft capsules in case of overdose?\u003c\/h3\u003e \u003cu\u003eSymptoms in case of overdose\u003c\/u\u003e Symptoms of overdose may manifest themselves with central nervous system symptoms such as headache, dizziness, light-headedness and loss of consciousness (myoclonic convulsions even in children), abdominal pain, nausea, vomiting, gastrointestinal bleeding and liver and kidney dysfunction, hypotension, respiratory depression and cyanosis. In cases of severe poisoning, metabolic acidosis may occur. \u003cu\u003eTherapeutic measures in case of overdose\u003c\/u\u003e There is no specific antidote. If after one hour of ingestion, the patient has potentially toxic levels of the drug, resort to oral administration of activated charcoal.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e  \u003ch3\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Buscofenact 400mg 12 soft capsules. \u003c\/h3\u003e\n\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage, cardiac malformations and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformations increased from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor resulted in increased pre- and post-implantation loss and embryo-foetal mortality. In addition, an increased incidence of malformations, including cardiovascular, has been reported in animals treated with a prostaglandin synthesis inhibitor during the organogenesis period. During the first and second trimester of pregnancy, ibuprofen should be administered only if clearly necessary. If ibuprofen is used in women attempting to conceive or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to the risk of: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligo-hydroamnios. At the end of pregnancy, the mother and the neonate are at: - possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses; - inhibition of uterine contractions which may result in a delay or prolongation of labor at delivery. Consequently, the administration of ibuprofen is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Ibuprofen and its metabolites may pass into breast milk in low concentrations. To date, no deleterious effects on nursing infants are known. Therefore, for short-term treatment of pain and fever at the recommended dose, it should not generally be necessary to stop breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e There is some evidence that drugs which inhibit cyclooxygenase\/prostaglandin synthesis may impair female fertility by affecting ovulation. Once treatment with ibuprofen has been stopped, the effect is reversible.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Buscofenact 400mg 12 soft capsules before driving or using machines - Does Buscofenact 400mg 12 soft capsules affect driving or using machines?\u003c\/h3\u003e Since the intake of BuscofenAct at the highest dosage may cause undesirable effects on the central nervous system, such as tiredness and dizziness, in isolated cases the ability to react promptly, the ability to drive and to use machines may be impaired. This applies especially if the use of BuscofenAct is associated with alcohol consumption.","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":51131207516487,"sku":"041631021","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-buscofenact-400mg-12-capsule-molli-farmacia-dottor-tili-1213792369.jpg?v=1767142330"},{"product_id":"buscopan-compositum-10mg-500mg-20-compresse-rivestite","title":"Buscopan Compositum 10mg + 500mg 20 coated tablets","description":"\u003cp\u003e\u003cb\u003eBuscopan Compositum 10mg + 500mg 20 coated tablets\u003c\/b\u003e is a drug formulated for the treatment of \u003cb\u003eparoxysmal pain\u003c\/b\u003e associated with gastrointestinal tract conditions and spastic pain. Each coated tablet contains two active ingredients: \u003cb\u003ehyoscine N-butylbromide\u003c\/b\u003e (10 mg) and \u003cb\u003eparacetamol\u003c\/b\u003e (500 mg), which act synergistically to relieve pain and reduce muscle spasms. This product is indicated to treat \u003cb\u003ebiliary tract dyskinesias\u003c\/b\u003e and other conditions that require antispasmodic and analgesic action. The tablets are designed to be swallowed whole, ensuring optimal release of the active ingredients. Buscopan Compositum is an effective solution for those seeking rapid and targeted relief from painful symptoms associated with gastrointestinal disorders.\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\n \u003ch3\u003eActive ingredients contained in Buscopan Compositum 10mg + 500mg 20 coated tablets - What is the active ingredient of Buscopan Compositum 10mg + 500mg 20 coated tablets?\u003c\/h3\u003e\n\n\u003cp\u003e \u003cb\u003eBuscopan Compositum 10 mg + 500 mg coated tablets\u003c\/b\u003e One coated tablet contains: \u003cb\u003eActive ingredients:\u003c\/b\u003e N-butyl hyoscine bromide 10 mg, paracetamol 500 mg \u003cb\u003eBuscopan Compositum 10 mg + 800 mg suppositories\u003c\/b\u003e One suppository contains: \u003cb\u003eActive ingredients:\u003c\/b\u003e N-butyl hyoscine bromide 10 mg, paracetamol 800 mg Excipient with known effect: sodium. For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Composition of Buscopan Compositum 10mg + 500mg 20 coated tablets - What does Buscopan Compositum 10mg + 500mg 20 coated tablets contain?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cb\u003eCoated tablets\u003c\/b\u003e : \u003cu\u003eCore\u003c\/u\u003e : microcrystalline cellulose, sodium carmellose, maize starch, ethylcellulose, colloidal silica, magnesium stearate. \u003cu\u003eCoating\u003c\/u\u003e : hypromellose, polyacrylates, titanium dioxide, macrogol 6000, talc, silicone antifoaming agent. \u003cb\u003eSuppositories\u003c\/b\u003e : glyceride esters of saturated fatty acids, soya lecithin.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Therapeutic indications Buscopan Compositum 10mg + 500mg 20 coated tablets - Why is Buscopan Compositum 10mg + 500mg 20 coated tablets used? What is it used for?\u003c\/h3\u003e\n\n\u003cp\u003e Paroxysmal pain in gastrointestinal tract conditions, spastic pain, dyskinesia of the biliary tract.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Contraindications Buscopan Compositum 10mg + 500mg 20 coated tablets - When should Buscopan Compositum 10mg + 500mg 20 coated tablets not be used?\u003c\/h3\u003e\n\n \u003cp\u003eBuscopan Compositum is contraindicated in case of: - hypersensitivity to the active ingredients (hyoscine N-butylbromide and paracetamol), to nonsteroidal anti-inflammatory drugs or to any of the excipients listed in paragraph 6.1; - acute angle glaucoma; - prostatic hypertrophy or other causes of urinary retention; - mechanical stenosis of the gastrointestinal tract; - pyloric stenosis and other conditions stenosing the gastrointestinal tract; - paralytic or obstructive ileus; - megacolon; - ulcerative colitis; - reflux esophagitis; - intestinal atony in the elderly and debilitated subjects; - myasthenia gravis; - pediatric age; - paracetamol-based products are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those affected by severe haemolytic anaemia; - severe hepatocellular insufficiency (Child - Pugh C). \u003cb\u003e\u003ci\u003eThe use of Buscopan Compositum is contraindicated in case of rare hereditary conditions that may be incompatible with an excipient of the product (see paragraph 4.4).\u003c\/i\u003e\u003c\/b\u003e Buscopan Compositum 10 mg + 800 mg suppositories must not be used in patients with a history of allergy to soya or peanuts.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\n\u003ch3\u003e Quantity and method of taking Buscopan Compositum 10mg + 500mg 20 coated tablets - How to take Buscopan Compositum 10mg + 500mg 20 coated tablets?\u003c\/h3\u003e\n\n\u003cp\u003e The following dosage is recommended for adults, unless otherwise prescribed by your doctor: \u003cu\u003eCoated tablets\u003c\/u\u003e 1-2 tablets 3 times a day. Do not exceed 6 tablets per day. The tablets should not be chewed, but swallowed whole with a sufficient amount of water. \u003cu\u003eSuppositories\u003c\/u\u003e 1 suppository 3-4 times a day. Do not exceed 4 suppositories per day. \u003cu\u003eDuration of treatment\u003c\/u\u003e Buscopan Compositum should not be taken for more than three days unless prescribed by your doctor (see section 4.4). \u003cb\u003e\u003ci\u003ePaediatric population\u003c\/i\u003e\u003c\/b\u003e The use of Buscopan Compositum is not recommended in children under 10 years of age. The concomitant administration of other drugs containing paracetamol may require a dosage adjustment, see section 4.4.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\n \u003ch3\u003eStorage Buscopan Compositum 10mg + 500mg 20 coated tablets - How to store Buscopan Compositum 10mg + 500mg 20 coated tablets?\u003c\/h3\u003e\n\n\u003cp\u003e Coated tablets: store below 25°C. Suppositories: store below 30°C.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\n\u003ch3\u003e Warnings Buscopan Compositum 10mg + 500mg 20 coated tablets - About Buscopan Compositum 10mg + 500mg 20 coated tablets it is important to know that:\u003c\/h3\u003e\n\n \u003cp\u003eBuscopan Compositum should not be taken for more than 3 days unless directed by your doctor. Instruct the patient to contact their doctor if the pain persists or worsens, if new symptoms occur, or if redness or swelling occurs as these may be symptoms of a serious condition. In case of severe abdominal pain of unknown origin that persists, worsens or is accompanied by symptoms such as fever, nausea, vomiting, altered bowel movements, distended abdomen, drop in blood pressure, fainting or blood in the stool, seek medical advice immediately. To prevent overdose, ensure that other medicines taken at the same time do not contain paracetamol, one of the active substances of Buscopan Compositum. Liver damage may occur if the recommended dosage of paracetamol is exceeded (see section 4.9). Buscopan Compositum should be used with caution in case of: • glucose-6-phosphate dehydrogenase insufficiency; • liver dysfunction (e.g. due to chronic alcohol abuse, hepatitis); • chronic alcohol use even if recently stopped; • impaired renal function; • Gilbert's syndrome; • mild to moderate hepatocellular insufficiency (Child - Pugh A\/B); • low glutathione reserves. \u003cb\u003eAdminister with caution to subjects with renal or hepatic insufficiency.\u003c\/b\u003e In such conditions Buscopan Compositum should be administered only under medical supervision, if necessary, reducing the dose or prolonging the interval between individual administrations. Blood count and renal and hepatic function should be monitored after prolonged use. The extensive use of analgesics, especially at high doses, may induce headache which should not be treated with increased doses of the medicinal product. Severe acute hypersensitivity reactions (e.g. anaphylactic shock) are observed very rarely. Treatment should be discontinued at the first signs of a hypersensitivity reaction following the administration of Buscopan Compositum. Serious skin reactions: Life-threatening reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with the use of Buscopan Compositum. Patients should be informed of the signs and symptoms and monitored closely for skin reactions. If symptoms or signs of Stevens-Johnson syndrome or toxic epidermal necrolysis (e.g. progressive skin rash with blisters or mucosal lesions) occur, the patient should immediately stop treatment with Buscopan Compositum and consult a doctor. Hepatotoxicity with paracetamol may occur even at therapeutic doses, after short-term treatment and in patients without pre-existing liver dysfunction (see section 4.8). Abrupt cessation of analgesics after prolonged use at high doses may cause withdrawal symptoms (e.g. headache, tiredness, nervousness), which usually resolve within a few days. Resumption of analgesics should be subject to medical advice and to the resolution of withdrawal symptoms. Due to the potential risk of anticholinergic complications, it should be used with caution in patients predisposed to narrow-angle glaucoma, in patients subject to intestinal or urinary tract obstruction and in those prone to tachyarrhythmia with disorders of the central autonomic nervous system, in tachyarrhythmias, in arterial hypertension, in congestive heart failure and in hyperthyroidism. All antimuscarinics reduce the volume of bronchial secretions; therefore they should be used with caution in patients with chronic obstructive inflammatory diseases of the respiratory system. During treatment with paracetamol, before taking any other drug, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur, see section 4.2. Instruct the patient to contact the doctor before combining any other drug. See also section 4.5. Buscopan Compositum 10 mg + 500 mg tablets contain 4.32 mg sodium per tablet, i.e. less than 1 mmol (23 mg) sodium, i.e. it is essentially “sodium-free”.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Interactions Buscopan Compositum 10mg + 500mg 20 coated tablets - Which medicines or foods can modify the effect of Buscopan Compositum 10mg + 500mg 20 coated tablets?\u003c\/h3\u003e\n\n \u003cp\u003eUse with extreme caution and under close monitoring during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, hypnotics and antiepileptics such as glutethimide, phenobarbital, carbamazepine, phenytoin). The same situation occurs with potentially hepatotoxic substances and with alcohol abuse. Concomitant administration of chloramphenicol may induce a prolongation of the half-life of chloramphenicol, with the risk of increasing its toxicity. Paracetamol may increase the risk of bleeding in patients taking warfarin and other vitamin K antagonists. Patients taking paracetamol and vitamin K antagonists should be monitored for appropriate coagulation and for the occurrence of bleeding. Co-administration of flucloxacillin with paracetamol may lead to metabolic acidosis in patients with risk factors for glutathione depletion. Concomitant use of paracetamol and zidovudine (AZT or retrovir) increases the tendency to reduce leukocytes (neutropenia). Therefore Buscopan Compositum should be taken together with zidovudine only under medical supervision. Probenecid inhibits the binding of paracetamol to glucuronic acid, thereby reducing the clearance of paracetamol by approximately a factor of 2. The dose of paracetamol should therefore be reduced during concomitant administration with probenecid. Cholestyramine reduces the absorption of paracetamol. The anticholinergic effect of medicinal products such as tri- and tetracyclic antidepressants, antihistamines, antipsychotics, quinidine, amantadine, disopyramide and other anticholinergics (e.g. tiotropium, ipratropium, atropine-like substances) may be potentiated by Buscopan Compositum. Concomitant treatment with dopamine antagonists, such as metoclopramide, may reduce the effect of both drugs on the gastrointestinal tract. Tachycardia induced by β-adrenergic drugs may be potentiated by Buscopan Compositum. The tachycardic effects of beta-adrenergic agents may be intensified by Buscopan Compositum. \u003ci\u003eInterference with laboratory tests\u003c\/i\u003e Paracetamol intake may affect the determination of uric acid by the phosphotungstic acid method and of blood glucose by the glucose oxidase-peroxidase method. \u003ci\u003eIn addition for oral use\u003c\/i\u003e : Drugs that slow gastric emptying (e.g. propantheline) can reduce the rate of absorption of paracetamol, delaying its therapeutic effect; on the contrary, drugs that increase the rate of gastric emptying (e.g. metoclopramide or domperidone) lead to an increase in the rate of absorption of paracetamol.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Like all medicines, Buscopan Compositum 10mg + 500mg 20 coated tablets can cause side effects - What are the side effects of Buscopan Compositum 10mg + 500mg 20 coated tablets?\u003c\/h3\u003e\n\n \u003cp\u003eAdverse reactions are listed below by system organ class and frequency, using the following categories: Very common: ≥ 1\/10 Common: ≥ 1\/100, \u0026lt; 1\/10 Uncommon: ≥ 1\/1,000, \u0026lt; 1\/100 Rare: ≥ 1\/10,000, \u0026lt; 1\/1,000 Very rare: \u0026lt; 1\/10,000 Not known: frequency cannot be estimated from the available data. \u003cu\u003eBlood and lymphatic system disorders\u003c\/u\u003e Not known: pancytopenia, agranulocytosis, thrombocytopenia, neutropenia, leucopenia, haemolytic anaemia. \u003cu\u003eImmune system disorders, Skin and subcutaneous tissue disorders\u003c\/u\u003e Uncommon: skin reactions, abnormal sweating, pruritus, nausea. Rare: erythema, decreased blood pressure including shock. Very rare: urticaria, rash, exanthema, severe skin reactions (such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and generalized exanthematous pustulosis (AGEP)). Not known: anaphylactic shock, anaphylactic reactions, drug skin reaction, dyspnoea, hypersensitivity, angioedema, fixed drug eruption. \u003cu\u003eCardiac disorders\u003c\/u\u003e . Rare: tachycardia. \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e . Not known: bronchial muscle spasms (especially in patients with a history of bronchial asthma or allergy). \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e . Uncommon: dry mouth. \u003cu\u003eHepatobiliary disorders\u003c\/u\u003e . Not known: increased transaminases, cytolytic hepatitis which may lead to acute liver failure. \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e . Not known: urinary retention. Cases of erythema multiforme have been reported with the use of paracetamol. Hypersensitivity reactions such as angioedema, laryngeal edema have been reported. The following undesirable effects have also been reported: anaemia, changes in liver function and hepatitis, changes in kidney function (acute renal failure, interstitial nephritis, haematuria, anuria), gastrointestinal reactions and dizziness. Drowsiness, mydriasis, accommodation disorders, increased ocular tone, constipation and difficulty urinating have also been reported. \u003cu\u003eAdditional adverse reactions only for suppositories\u003c\/u\u003e \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e . Not known: anorectal discomfort. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eOVERDOSE\u003c\/h2\u003e\n\n\u003ch3\u003e Overdose Buscopan Compositum 10mg + 500mg 20 coated tablets - What are the risks of Buscopan Compositum 10mg + 500mg 20 coated tablets in case of overdose?\u003c\/h3\u003e\n\n \u003cp\u003eDue to paracetamol overdose, elderly people, young children, patients with liver disease, chronic alcohol consumption or chronic malnutrition, as well as patients treated with enzyme-inducing drugs are at increased risk of intoxication, even with fatal outcome. \u003cb\u003e\u003ci\u003eSymptoms\u003c\/i\u003e\u003c\/b\u003e \u003ci\u003e\u003cu\u003eHyoscine N-butylbromide\u003c\/u\u003e\u003c\/i\u003e In case of overdose, anticholinergic effects have been observed. \u003ci\u003e\u003cu\u003eParacetamol\u003c\/u\u003e\u003c\/i\u003e In cases of chronic intoxication, haemolytic anaemia, cyanosis, weakness, dizziness, paraesthesia, tremors, insomnia, headache, memory loss, central nervous system irritation phenomena, delirium and convulsions may occur. Symptoms usually appear during the first 24 hours and include pallor, nausea, vomiting, anorexia and abdominal pain. Patients may then experience a temporary subjective improvement but mild abdominal pain, perhaps indicative of liver damage, may persist; a considerable increase in transaminases, jaundice, coagulation disorders, hypoglycaemia and progression to hepatic coma may occur. A single dose of paracetamol of approximately 6 g or more in adults or 140 mg\/kg in children may cause hepatocellular necrosis. This may induce irreversible complete necrosis and subsequently hepatocellular failure, gastrointestinal bleeding, metabolic acidosis, encephalopathy and disseminated intravascular coagulation which may progress to coma and death. Concurrent increases in liver transaminases (AST, ALT), lactate dehydrogenase and bilirubin with reduction in prothrombin levels and an increase in prothrombin time have been observed, occurring 12 - 48 hours after ingestion. Clinical symptoms of liver damage are usually evident after 2 days and reach a maximum after 4 - 6 days. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Other non-hepatic symptoms such as myocardial abnormalities, pancytopenia and pancreatitis have also been reported and should be considered after paracetamol overdose. \u003cb\u003e\u003ci\u003eTherapy\u003c\/i\u003e\u003c\/b\u003e \u003ci\u003e\u003cu\u003eHyoscine N-butylbromide\u003c\/u\u003e\u003c\/i\u003e If required, parasympathomimetic medicinal products should be administered. In cases of glaucoma, an ophthalmological examination should be performed urgently. Cardiovascular complications should be treated according to the usual therapeutic principles. In case of respiratory paralysis, intubation and artificial respiration should be considered. For urinary retention, catheterization may be necessary. In addition, appropriate supportive measures should be used as necessary. \u003ci\u003e\u003cu\u003eParacetamol\u003c\/u\u003e\u003c\/i\u003e Where paracetamol intoxication is suspected, intravenous administration of group SH donors such as N-acetylcysteine ​​within the first 10 hours of ingestion is indicated. Although N-acetylcysteine ​​is most effective if given within this period, it may still offer some protection if given 48 hours after ingestion; in this case, it should be taken for a longer period. Plasma paracetamol concentrations may be lowered by dialysis. Quantitative analyses of plasma paracetamol concentrations are recommended. Further measures will depend on the severity, nature and course of clinical symptoms of paracetamol intoxication and should follow standard intensive care protocols.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Buscopan Compositum 10mg + 500mg 20 coated tablets.\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e There are no adequate data on the use of Buscopan Compositum during pregnancy. Long-term experience with the two substances in monotherapy has indicated insufficient evidence of adverse effects during pregnancy in women. After the use of hyoscine N-butylbromide, preclinical studies in rats and rabbits have shown neither embryotoxic nor teratogenic effects. During pregnancy, potential data on paracetamol overdose have not shown an increased risk of malformations. Reproduction studies to investigate oral use have not shown signs suggesting malformations of foetotoxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, under normal conditions of use, paracetamol can be taken during pregnancy after careful consideration of the risk-benefit ratio. During pregnancy, paracetamol should not be taken for prolonged periods, at high doses, or in combination with other medicinal products since safety has not been confirmed in such cases. Therefore, Buscopan Compositum is not recommended during pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e The safety of hyoscine N-butylbromide during breastfeeding has not yet been established. Paracetamol is excreted in breast milk. However, at therapeutic doses it is expected that it does not cause undesirable effects in the newborn. The decision whether to continue or discontinue breastfeeding or to continue or discontinue therapy with Buscopan Compositum must be made taking into account the benefit of breastfeeding for the child and the benefit of therapy with Buscopan Compositum for the mother. \u003cu\u003eFertility\u003c\/u\u003e No studies on the effects on fertility in humans have been performed (see section 5.3).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\n\u003ch3\u003e Taking Buscopan Compositum 10mg + 500mg 20 coated tablets before driving or using machines - Does Buscopan Compositum 10mg + 500mg 20 coated tablets affect driving or using machines?\u003c\/h3\u003e\n\n\u003cp\u003e No studies on the ability to drive and use machines have been performed. However, anticholinergics can induce visual accommodation disorders and drowsiness, which must be taken into account by those who drive vehicles or machines or carry out tasks requiring an intact level of alertness.\u003c\/p\u003e","brand":"OPELLA HEALTHCARE ITALY Srl","offers":[{"title":"Default Title","offer_id":51131311784263,"sku":"029454042","price":13.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/opella-healthcare-italy-srl-buscopan-compositum-10mg-500mg-20-compresse-rivestite-farmacia-dottor-tili-1213792120.jpg?v=1767135406"},{"product_id":"buscofenpocket-400mg-10-bustine-polvere-orale","title":"BuscofenPocket 400mg 10 sachets oral powder ","description":"\u003cdiv class=\"flex max-w-full flex-col flex-grow\"\u003e\n\n\u003cdiv data-message-author-role=\"assistant\" data-message-id=\"d6a1811d-9dfb-4410-93e2-2f9a94da0761\" dir=\"auto\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 whitespace-normal break-words text-start [.text-message+\u0026amp;]:mt-5\" data-message-model-slug=\"gpt-4o\"\u003e\n\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\"\u003e\n\n\u003cdiv class=\"markdown prose w-full break-words dark:prose-invert light\"\u003e\u003c\/div\u003e\n\n\n\u003c\/div\u003e\n\n\n\u003c\/div\u003e\n\n\n\u003c\/div\u003e\n\n\u003cp data-start=\"0\" data-end=\"449\" data-is-last-node=\"\" data-is-only-node=\"\"\u003e \u003cstrong data-start=\"0\" data-end=\"25\" data-is-only-node=\"\"\u003eBuscofenPocket 400 mg\u003c\/strong\u003e is a \u003cstrong data-start=\"31\" data-end=\"68\"\u003epainkiller and anti-inflammatory\u003c\/strong\u003e based on \u003cstrong data-start=\"79\" data-end=\"93\"\u003eibuprofen\u003c\/strong\u003e , indicated for the rapid and effective treatment of \u003cstrong data-start=\"145\" data-end=\"193\"\u003eheadaches, toothaches, menstrual pain\u003c\/strong\u003e and feverish states. Thanks to its formulation in \u003cstrong data-start=\"244\" data-end=\"278\"\u003esachets of orosoluble powder\u003c\/strong\u003e , it is taken without water, ensuring rapid action against pain and inflammation. \u003cstrong data-start=\"367\" data-end=\"383\"\u003eNSAID drug\u003c\/strong\u003e , helps reduce discomfort and improve daily well-being.\u003c\/p\u003e\n\n\u003ch2\u003e\u003c\/h2\u003e\n\n\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\n \u003ch3\u003eActive ingredients contained in Buscofenpocket 400mg 10 sachets oral powder - What is the active ingredient of Buscofenpocket 400mg 10 sachets oral powder?\u003c\/h3\u003e\n\n\u003cp\u003e Each single-dose sachet contains ibuprofen 400 mg. Excipient with known effect: isomaltitol (E953) For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Composition of Buscofenpocket 400mg 10 sachets oral powder - What does Buscofenpocket 400mg 10 sachets oral powder contain?\u003c\/h3\u003e\n\n\u003cp\u003e Isomaltitol (E953), Citric acid, Acesulfame potassium (E 950), Glycerol distearate (Type I), Lemon flavour 502336 TP0551 (contains corn maltodextrin, alpha tocopherol (E 307)).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Therapeutic indications Buscofenpocket 400mg 10 sachets oral powder - Why is Buscofenpocket 400mg 10 sachets oral powder used? What is it used for?\u003c\/h3\u003e\n\n \u003cp\u003eBUSCOFENPOCKET is indicated for the short-term symptomatic treatment of mild-moderate pain such as headache, toothache and dysmenorrhea. BUSCOFENPOCKET is also indicated for the short-term symptomatic treatment of fever. BUSCOFENPOCKET 400 mg is recommended for adults and adolescents with a body weight of 40 kg or more (aged 12 years or over).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Contraindications Buscofenpocket 400mg 10 sachets oral powder - When should Buscofenpocket 400mg 10 sachets oral powder not be used?\u003c\/h3\u003e\n\n \u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. - Patients with a history of bronchospasm, asthma, rhinitis, urticaria or angioedema associated with the intake of acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs. - History of gastrointestinal bleeding or perforation related to previous NSAID therapy. - Presence or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). - Cerebrovascular haemorrhage or other active haemorrhage. - Patients with severe hepatic insufficiency, severe renal insufficiency (glomerular filtration rate less than 30 ml\/min) or severe cardiac insufficiency (NYHA class IV) (see section 4.4). - Severe dehydration (due to vomiting, diarrhoea or insufficient fluid intake). - Haematopoietic disorders of unknown origin, e.g. thrombocytopenia. - During the last trimester of pregnancy (see section 4.6).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\n\u003ch3\u003e Quantity and method of taking Buscofenpocket 400mg 10 sachets oral powder - How do you take Buscofenpocket 400mg 10 sachets oral powder?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e For short-term use only. Undesirable effects may be limited by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). Adults should consult a doctor if symptoms worsen or if the use of the medicine is required for more than 3 days in case of fever or more than 4 days in case of pain. Consult a doctor if symptoms worsen in adolescents over 12 years of age or if the use of this medicine is required for more than 3 days. \u003cu\u003eAdults and adolescents with a body weight of 40 kg or more (aged 12 years or over)\u003c\/u\u003e The initial dose is 1 sachet of BUSCOFENPOCKET 400 mg. If necessary, an additional sachet of BUSCOFENPOCKET 400 mg may be taken. The interval between doses should be chosen in line with the symptoms observed and the maximum recommended daily dose. It should not be less than six hours. Do not exceed the dose of 1200 mg (3 sachets of BUSCOFENPOCKET 400 mg) in 24 hours. \u003cu\u003eChildren under 12 years of age and adolescents with body weight \u0026lt; 40 kg\u003c\/u\u003e BUSCOFENPOCKET 400 mg is not suitable for children under 12 years of age and adolescents with body weight \u0026lt; 40 kg. \u003cu\u003eElderly\u003c\/u\u003e In elderly patients, the dosage is the same as for adults, but greater caution is required (see section 4.4). \u003cu\u003eImpaired hepatic or renal function\u003c\/u\u003e BUSCOFENPOCKET 400 mg is contraindicated in patients with severe hepatic insufficiency or severe renal insufficiency (see section 4.3). In patients with mild-moderate impairment of renal or hepatic function, a dose reduction is not necessary, however greater caution is required (see section 4.4). \u003cu\u003eMethod of administration\u003c\/u\u003e Oral use. Place the oral powder on the tongue, let it dissolve and then swallow it; water is not necessary. It is recommended to take it during meals, especially for people with a delicate stomach.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\n\u003ch3\u003e Storage Buscofenpocket 400mg 10 sachets oral powder - How do you store Buscofenpocket 400mg 10 sachets oral powder?\u003c\/h3\u003e\n\n\u003cp\u003e Do not store above 25°C. Store in the original package in order to protect from light.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\n\u003ch3\u003e Warnings Buscofenpocket 400mg 10 sachets oral powder - About Buscofenpocket 400mg 10 sachets oral powder it is important to know that:\u003c\/h3\u003e\n\n \u003cp\u003eCaution is advised in patients: - with a history of hypertension and\/or heart failure, since fluid retention and oedema have been reported in association with NSAID therapy (see sections 4.3 and 4.8); - with renal impairment, since further deterioration of renal function may occur (see sections 4.3 and 4.8); - with liver dysfunction (see sections 4.3 and 4.8); - who have just undergone major surgery; - with congenital impairment of porphyrin metabolism (e.g. acute intermittent porphyria). Undesirable effects may be limited by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2 and subsequent sections on gastrointestinal and cardiovascular risks). \u003cu\u003eRespiratory disorders\u003c\/u\u003e Bronchospasm may occur in patients with bronchial asthma or allergic disease or with a history of these conditions. \u003cu\u003eElderly\u003c\/u\u003e Elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.8). \u003cu\u003eGastrointestinal safety\u003c\/u\u003e Life-threatening gastrointestinal bleeding, ulceration and perforation have been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in the elderly. These patients should start treatment on the lowest dose available. For these patients, as well as for patients requiring concomitant use of low dose aspirin or other drugs likely to increase gastrointestinal risk (see below and section 4.5), combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered. Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) particularly during the initial stages of treatment. Caution is advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as aspirin (see section 4.5). If gastrointestinal bleeding or ulceration occurs in patients receiving ibuprofen, the treatment should be withdrawn (see section 4.3). NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). \u003cu\u003eSevere skin reactions\u003c\/u\u003e Very rarely, serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk of developing these reactions early in therapy: the onset of the reaction occurs in the majority of cases within the first month of treatment. Acute generalized exanthematous pustulosis (AGEP) has been reported in connection with medicinal products containing ibuprofen. Therapy with BUSCOFENPOCKET should be discontinued if skin rash, mucosal lesions, or any other sign of hypersensitivity appears. Exceptionally, chickenpox may be the cause of serious infectious complications affecting the skin and soft tissues. It is recommended to avoid the use of ibuprofen during chickenpox. \u003cu\u003eMasking of symptoms of underlying infections\u003c\/u\u003e BUSCOFENPOCKET may mask the symptoms of infection, which may delay initiation of adequate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When BUSCOFENPOCKET is administered for the relief of infection-related fever or pain, monitoring for infection is advised. In non-hospital settings, the patient should seek medical advice if symptoms persist or worsen. \u003cu\u003eSystemic lupus erythematosus and mixed connective tissue disease\u003c\/u\u003e Caution is advised in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease, as they may be at increased risk of aseptic meningitis (see section 4.8). \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e Caution is advised (also discuss with your doctor or pharmacist) before initiating treatment in patients with a history of hypertension and\/or mild-moderate congestive heart failure, since fluid retention, hypertension and oedema have been reported in association with NSAID therapy. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with ibuprofen only after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be made before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), especially if high doses of ibuprofen (2400 mg\/day) are required. \u003cu\u003eAllergic reactions\u003c\/u\u003e Severe acute hypersensitivity reactions (e.g. anaphylactic shock) are observed very rarely. At the first signs of a hypersensitivity reaction following the intake\/administration of BUSCOFENPOCKET, therapy should be discontinued. The required medical measures should be implemented by specialized personnel, depending on the symptoms. Caution is advised in patients who have had allergic or hypersensitivity reactions, as these patients may be at increased risk of experiencing hypersensitivity reactions following intake of Ibuprofen. There is an increased risk of allergic reactions in patients suffering from hay fever, nasal polyps or chronic obstructive respiratory disease. These reactions may present as asthma attacks (so-called analgesic asthma), Quincke's oedema or urticaria. \u003cu\u003eRenal effects\u003c\/u\u003e In general, habitual use of analgesics, particularly combinations of several analgesic active ingredients, may lead to permanent kidney damage with risk of renal failure (analgesic nephropathy). This risk may be increased by physical exertion associated with salt loss and dehydration and should therefore be avoided. Caution is advised in patients with hypertension and\/or heart failure, as further deterioration of renal function may occur (see sections 4.3 and 4.8). \u003cu\u003eOther notes\u003c\/u\u003e Ibuprofen, the active substance of BUSCOFENPOCKET, may temporarily inhibit platelet function (platelet aggregation). Therefore, patients with coagulation disorders should be carefully monitored. In case of prolonged administration of BUSCOFENPOCKET, periodic checks of liver values, renal function and blood counts are necessary. The use of the medicinal product together with other NSAIDs, including cyclooxygenase-2 selective inhibitors, should be avoided, due to potential additive effects (see section 4.5). These effects may worsen with prolonged use of any type of headache painkiller. If this situation occurs or is suspected, a doctor should be consulted and treatment should be discontinued. The diagnosis of medication overuse headache (MOH) should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of headache medications. Alcohol consumption should be avoided as it may increase the side effects of NSAIDs, particularly those affecting the gastrointestinal tract and the central nervous system. \u003cu\u003ePaediatric population\u003c\/u\u003e There is a risk of renal impairment in dehydrated adolescents. \u003cb\u003eInformation on some of the excipients\u003c\/b\u003e This medicinal product contains isomaltitol (E953): Patients with rare hereditary problems of fructose intolerance should not take this medicine. This medicinal product contains potassium, less than 1 mmol (39 mg) per sachet, i.e. essentially “potassium-free”.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Interactions Buscofenpocket 400mg 10 sachets oral powder - Which medicines or foods can modify the effect of Buscofenpocket 400mg 10 sachets oral powder?\u003c\/h3\u003e\n\n \u003cp\u003eFor patients taking ibuprofen concomitantly with the medicinal products listed below, monitoring of clinical and biological parameters should be considered. \u003cu\u003eThe use of ibuprofen in combination with the following medicinal products is not recommended\u003c\/u\u003e : • \u003ci\u003eOther NSAIDs, including cyclooxygenase-2 selective inhibitors\u003c\/i\u003e : use in combination with other NSAIDs, including COX-2 inhibitors, should be avoided due to the potential for additive effects (see section 4.4). The concomitant use of several NSAIDs may increase the risk of gastrointestinal ulcers and bleeding due to the synergistic effect. • Acetylsalicylic acid. The concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effects are considered likely with occasional use of ibuprofen (see section 5.1). \u003cu\u003eIbuprofen should be used with caution in combination with the following medicinal products\u003c\/u\u003e : \u003ci\u003eDiuretics, ACE inhibitors, beta-blocking drugs and angiotensin-II antagonists\u003c\/i\u003e . NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of nephrotoxicity associated with NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function), the co-administration of an ACE inhibitor, a beta-blocking medicinal product or an angiotensin-II antagonist and agents that inhibit cyclooxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, this combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and periodically thereafter. Concomitant administration of BUSCOFENPOCKET and potassium-sparing diuretics may cause hyperkalemia. \u003ci\u003eCardiac glycosides\u003c\/i\u003e NSAIDs may exacerbate heart failure, reduce glomerular filtration and increase plasma levels of cardiac glycosides (e.g. digoxin). \u003ci\u003eLithium\u003c\/i\u003e Concomitant administration of ibuprofen and lithium-containing medicinal products may cause an increase in serum lithium levels. \u003ci\u003ePhenytoin\u003c\/i\u003e NSAIDs may reduce the elimination of phenytoin. \u003ci\u003eMethotrexate\u003c\/i\u003e There is evidence of a possible increase in plasma levels of methotrexate. NSAIDs inhibit the tubular secretion of methotrexate and may reduce its clearance. In case of treatment with high-dose methotrexate, the administration of ibuprofen (NSAIDs) should be avoided. The risk of interaction between NSAIDs and methotrexate must be taken into account even in case of treatment with low-dose methotrexate, especially in patients with renal impairment. If methotrexate and NSAIDs are combined, renal function should be monitored. Caution is advised if NSAIDs and methotrexate are administered within 24 hours, as plasma levels of methotrexate may increase, resulting in increased toxicity. \u003ci\u003eTacrolimus\u003c\/i\u003e Increased risk of nephrotoxicity when the two medicinal products are administered concomitantly. \u003ci\u003eCiclosporin\u003c\/i\u003e Increased risk of nephrotoxicity when NSAIDs are administered concomitantly. \u003ci\u003eMifepristone\u003c\/i\u003e Due to the antiprostaglandin properties of NSAIDs, a decrease in the efficacy of the medicinal product may theoretically occur. Limited evidence suggests that co-administration of NSAIDs on the day of prostaglandin administration does not adversely influence the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination. \u003ci\u003eCorticosteroids\u003c\/i\u003e Increased risk of gastrointestinal ulceration or bleeding (see section 4.4). \u003ci\u003eAnticoagulants\u003c\/i\u003e NSAIDs may enhance the effects of anticoagulants such as warfarin (see section 4.4). \u003ci\u003eAntiplatelet agents and selective serotonin reuptake inhibitors (SSRIs)\u003c\/i\u003e Increased risk of gastrointestinal bleeding (see section 4.4). \u003ci\u003eSulfonylureas\u003c\/i\u003e NSAIDs may enhance the effect of sulfonylureas. Rare cases of hypoglycaemia have been reported in patients receiving sulfonylureas who were taking ibuprofen. During concomitant administration, monitoring of blood glucose levels is recommended as a precaution. \u003ci\u003eZidovudine\u003c\/i\u003e Increased risk of haematological toxicity when NSAIDs are administered concomitantly with zidovudine. There is evidence of an increased risk of haemarthrosis and haematoma in HIV-positive haemophiliacs when treated concomitantly with zidovudine and ibuprofen. \u003ci\u003eProbenecid and sulfinpyrazone\u003c\/i\u003e Medicines containing probenecid or sulfinpyrazone may delay the excretion of ibuprofen. The uricosuric action of these substances is decreased. \u003ci\u003eAminoglycosides\u003c\/i\u003e NSAIDs may decrease the excretion of aminoglycosides. \u003ci\u003eQuinolone antibiotics\u003c\/i\u003e Animal data indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of developing convulsions. \u003ci\u003eCYP2C9 inhibitors\u003c\/i\u003e Concomitant administration of ibuprofen with CYP2C9 inhibitors may increase the exposure to ibuprofen (CYP2C9 substrate). In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an approximately 80-100% increased exposure to S-(+)-ibuprofen was observed. Consideration should be given to reducing the ibuprofen dose when strong CYP2C9 inhibitors are co-administered, particularly when high doses of ibuprofen are administered with voriconazole or fluconazole. \u003ci\u003eCholestyramine\u003c\/i\u003e Concomitant administration of ibuprofen and cholestyramine delays and reduces the absorption of ibuprofen (25%). The medicines should be administered a few hours apart. \u003ci\u003eAlcohol, bisphosphonates, pentoxifylline (oxypentifylline)\u003c\/i\u003e Alcohol, bisphosphonates and pentoxifylline may increase gastrointestinal side effects and the risk of bleeding and ulceration. \u003ci\u003ePlant extracts\u003c\/i\u003e Ginkgo biloba may increase the risk of bleeding in association with NSAIDs.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Like all medicines, Buscofenpocket 400mg 10 sachets oral powder can cause side effects - What are the side effects of Buscofenpocket 400mg 10 sachets oral powder?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cb\u003eGastrointestinal disorders\u003c\/b\u003e : The most commonly observed adverse events are gastrointestinal in nature. Peptic ulceration, perforation or gastrointestinal bleeding, sometimes with fatal outcome, especially in the elderly, may occur. Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis and exacerbation of colitis and Crohn's disease have been reported following the administration of ibuprofen (see section 4.4). Less frequently, gastritis has been observed. \u003cb\u003eImmune system disorders\u003c\/b\u003e : Hypersensitivity reactions have been reported following treatment with ibuprofen, which may consist of: (a) non-specific allergic reactions and anaphylaxis, (b) respiratory tract reactivity, including asthma, including severe asthma, bronchospasm or dyspnoea, or (c) various skin disorders, including rashes of various types, pruritus, urticaria, purpura, angioedema and, very rarely, erythema multiforme, bullous dermatoses (including Stevens-Johnson syndrome and toxic epidermal necrolysis). \u003cb\u003eInfections and infestations\u003c\/b\u003e : Worsening of the inflammation associated with varicella-zoster virus infection (e.g. development of necrotising fasciitis) has been described in association with the use of ibuprofen. This is probably associated with the mechanism of action of NSAIDs. Therefore, if the patient notices the appearance or worsening of signs of infection while taking ibuprofen, it is recommended to seek medical advice immediately. Whether there is an indication for anti-infective\/antibiotic therapy should be investigated. \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e : In exceptional cases, serious skin infections and soft tissue complications may occur in the course of varicella infection (see section 4.4). \u003cb\u003eCardiac and vascular disorders\u003c\/b\u003e : Oedema, hypertension and cardiac failure have been reported in association with NSAID therapy. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a modest increased risk of arterial thrombotic events, such as myocardial infarction or stroke (see section 4.4). Adverse reactions possibly related to ibuprofen are listed below by frequency and MedDRA system organ class. Frequency groups are classified according to the following categories: very common (≥ 1\/10); common (≥ 1\/100 - \u0026lt; 1\/10); uncommon (≥ 1\/1,000 - \u0026lt; 1\/100); rare (≥ 1\/10,000 - \u0026lt; 1\/1,000); very rare (\u0026lt; 1\/10,000) and not known (cannot be estimated from the available data): \u003c\/p\u003e\n\n\u003ctable cellpadding=\"3\" cellspacing=\"0\" border=\"1\"\u003e\n\n\u003ctbody\u003e\n\n\u003ctr\u003e\n\n \u003ctd\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e\u003c\/td\u003e\n\n\u003ctd\u003e \u003cb\u003eFrequency\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e \u003cb\u003eSide effect\u003c\/b\u003e\n\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e Infections and infestations\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Rhinitis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Aseptic meningitis Symptoms of aseptic meningitis include headache, nausea, vomiting, fever, stiff neck, or loss of consciousness. Patients with certain immune system disorders (systemic lupus erythematosus or mixed connective tissue disease) appear to be at increased risk.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Pathologies of the haemolymphopoietic system\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n \u003ctd\u003ePancytopenia, anemia, leukopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anemia, haemolytic anemia. The first symptoms are: fever, sore throat, superficial mouth ulcers, flu-like symptoms, severe fatigue, unexplained bleeding and bruising. In these cases, the patient should be advised to immediately stop using the medicine in order to avoid any self-medication with analgesics or antipyretics and to consult a doctor. The blood count should be monitored regularly during long-term therapy.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e Immune system disorders\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Hypersensitivity reactions with skin rashes and itching, as well as asthma attacks (possibly with lowering of blood pressure). In this case the patient must inform the doctor immediately and stop taking BUSCOFENPOCKET.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n \u003ctd\u003eSevere hypersensitivity reactions Symptoms may include: swelling of the face, tongue and larynx with narrowing of the airways, dyspnea, tachycardia, hypotension (anaphylaxis, angioedema or severe shock). If any of these symptoms occur, which may occur on first use, immediate medical attention is needed.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"3\"\u003e Psychiatric disorders\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Insomnia, anxiety\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Depression, confusional state\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Psychotic reactions\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"3\"\u003e Nervous system disorders\u003c\/td\u003e\n\n\u003ctd\u003e Common\u003c\/td\u003e\n\n\u003ctd\u003e Headache, dizziness\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Paresthesia, drowsiness, agitation, irritability\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Optic neuritis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e Eye pathologies\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Visual impairment In these cases the patient should inform the doctor and stop taking ibuprofen\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Toxic Optic Neuropathy\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Ear and labyrinth pathologies\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Hearing impairment, vertigo, tinnitus\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Heart disease\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Heart failure, myocardial infarction (see also section 4.4)\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Vascular pathologies\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Arterial hypertension, vasculitis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n \u003ctd\u003eRespiratory, thoracic and mediastinal pathologies\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Asthma, bronchospasm, dyspnea\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"3\"\u003e Gastrointestinal disorders\u003c\/td\u003e\n\n\u003ctd\u003e Common\u003c\/td\u003e\n\n\u003ctd\u003e Heartburn, nausea, vomiting, diarrhea, constipation, flatulence, dyspepsia, abdominal pain, melaena, haematemesis, gastrointestinal haemorrhage\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Gastritis, gastrointestinal ulcers, potentially with bleeding and perforation, ulcerative stomatitis, exacerbation of colitis and Crohn's disease. The use of BUSCOFENPOCKET should be discontinued if the patient presents significant upper abdominal pain, vomits blood, presents blood in the stool or black stools\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Esophagitis, diaphragm-like intestinal stenosis, pancreatitis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e Hepatobiliary pathologies\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Hepatitis, jaundice, abnormal liver function\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Liver damage, especially with long-term treatment, liver failure\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"4\"\u003e Skin and subcutaneous tissue disorders\u003c\/td\u003e\n\n\u003ctd\u003e Common\u003c\/td\u003e\n\n\u003ctd\u003e Skin rashes (various)\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Urticaria, pruritus, purpura, angioedema, photosensitivity reactions\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n \u003ctd\u003eBullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome), erythema multiforme, alopecia\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e Acute generalized exanthematous pustulosis (AGEP). Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"3\"\u003e Kidney and urinary disorders\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Nephrotoxicity in various forms e.g. tubulointerstitial nephritis, nephrotic syndrome and renal failure\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Renal tissue damage (papillary necrosis), especially in long-term treatment, increased concentration of uric acid in the blood, increased concentration of urea in the blood\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Reduction of urine production and formation of edema, particularly in patients with arterial hypertension or renal insufficiency\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e Systemic disorders and conditions related to the administration site\u003c\/td\u003e\n\n\u003ctd\u003e Common\u003c\/td\u003e\n\n\u003ctd\u003e Fatigue\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Edema\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\n\u003c\/tbody\u003e\n\n\n\u003c\/table\u003e\n\n \u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\n\u003ch3\u003e Overdose Buscofenpocket 400mg 10 sachets oral powder - What are the risks of Buscofenpocket 400mg 10 sachets oral powder in case of overdose?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003eToxicity\u003c\/u\u003e In children or adults, signs and symptoms of toxicity have generally not been observed at doses below 100 mg\/kg. However, in some cases supportive treatment may be necessary. Children have been observed to show signs and symptoms of toxicity after ingestion of ibuprofen at doses of 400 mg\/kg or higher. In adults, the dose-response effect is less clear. The half-life in overdose is 1.5-3 hours. \u003cu\u003eSymptoms\u003c\/u\u003e Most patients who have ingested significant amounts of ibuprofen will experience symptoms within 4-6 hours. The most commonly reported symptoms of overdose include nausea, vomiting, abdominal pain, lethargy and somnolence. Central nervous system (CNS) effects include headache, tinnitus, dizziness, convulsions and loss of consciousness. Nystagmus, metabolic acidosis, hypothermia, renal effects, gastrointestinal bleeding, coma, apnea, CNS and respiratory depression have also been reported rarely. Cardiovascular toxicity including hypotension, bradycardia and tachycardia has been reported. In cases of severe poisoning, metabolic acidosis may occur. In cases of significant overdose, renal failure and liver damage may occur. \u003cu\u003eTreatment\u003c\/u\u003e There is no specific antidote for ibuprofen overdose. If the amount ingested in the previous hour exceeds 400 mg\/kg, oral administration of activated charcoal or gastric lavage followed by supportive measures is recommended. Contact your local poison control center for the most up-to-date information.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Buscofenpocket 400mg 10 sachets oral powder.\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryo-foetal development. Data from epidemiological studies suggest an increased risk of miscarriage, cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The risk is believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-foetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. Ibuprofen should not be given during the first and second trimester of pregnancy unless clearly necessary. If ibuprofen is used by women attempting to conceive or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. In the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at the end of pregnancy, to: - a possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses; - an inhibition of uterine contractions, resulting in delayed or prolonged labour. Consequently, ibuprofen is contraindicated during the third trimester of pregnancy (see section 4.3). \u003cu\u003eBreast-feeding\u003c\/u\u003e Only small amounts of ibuprofen and its metabolites are excreted in breast milk. Since no harmful effects on the newborn are known, it is not usually necessary to stop breast-feeding during short-term use of ibuprofen at recommended doses. \u003cu\u003eFertility\u003c\/u\u003e There is some evidence that substances which inhibit cyclooxygenase\/prostaglandin synthesis may impair female fertility by an effect on ovulation. This effect is reversible after cessation of treatment.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\n\u003ch3\u003e Taking Buscofenpocket 400mg 10 sachets oral powder before driving or using machinery - Does Buscofenpocket 400mg 10 sachets oral powder affect driving or using machinery?\u003c\/h3\u003e\n\n\u003cp\u003e When taken at the recommended doses, ibuprofen has a generally negligible influence on the ability to drive and use machines. Since side effects such as tiredness, dizziness and visual disturbances may occur with the use of ibuprofen, the ability to react and to actively participate in road traffic and to operate machinery may be impaired in isolated cases. This applies in particular in combination with alcohol.\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":51131365130567,"sku":"045386075","price":10.14,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-buscofenpocket-400mg-10-bustine-polvere-orale-farmacia-dottor-tili-1213791911.jpg?v=1767141970"},{"product_id":"buscofenact-400mg-20-capsule-molli","title":"Buscofenact 400mg 20 soft capsules","description":"\u003cp\u003eBuscofenact 400mg 20 softgels is a medicine formulated for the \u003cstrong\u003eshort-term symptomatic treatment\u003c\/strong\u003e of mild to moderate pain, such as headache, toothache and menstrual pain, as well as fever and pain associated with the common cold. Each softgel contains \u003cstrong\u003e400 mg of ibuprofen\u003c\/strong\u003e , an active ingredient known for its anti-inflammatory and analgesic properties. This medicine is indicated for adults and adolescents with a body weight of more than 40 kg (aged 12 years and over). The softgels are designed for quick and easy oral intake, ensuring rapid relief from symptoms. Ibuprofen works by inhibiting the synthesis of prostaglandins, chemicals in the body that cause inflammation and pain. \u003cstrong\u003eBuscofenact\u003c\/strong\u003e is an effective choice for those seeking quick and temporary relief from painful and feverish symptoms.\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\n \u003ch3\u003eActive ingredients contained in Buscofenact 400mg 20 soft capsules - What is the active ingredient of Buscofenact 400mg 20 soft capsules?\u003c\/h3\u003e\n\n\u003cp\u003e One soft capsule contains 400 mg ibuprofen. \u003cu\u003eExcipients with known effect\u003c\/u\u003e : Sorbitol 95.94 mg\/capsule (see section 4.4). For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Composition of Buscofenact 400mg 20 soft capsules - What does Buscofenact 400mg 20 soft capsules contain?\u003c\/h3\u003e\n\n\u003cp\u003e \u003ci\u003e\u003cu\u003eCapsule contents:\u003c\/u\u003e\u003c\/i\u003e Macrogol 600 Potassium hydroxide Purified water \u003ci\u003e\u003cu\u003eCapsule shell\u003c\/u\u003e\u003c\/i\u003e \u003cu\u003e:\u003c\/u\u003e Gelatin Liquid sorbitol Purified water \u003ci\u003e\u003cu\u003ePrinting ink\u003c\/u\u003e\u003c\/i\u003e Ingredients of Opacode WB black NS-78-17821: Black iron oxide (E172) Propylene glycol (E1520) Hypromellose 6cP\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Therapeutic indications Buscofenact 400mg 20 soft capsules - Why is Buscofenact 400mg 20 soft capsules used? What is it used for?\u003c\/h3\u003e\n\n \u003cp\u003eShort-term symptomatic treatment of: - mild to moderate pain such as headache, toothache and period pain; - fever and pain associated with the common cold. BuscofenAct is indicated in adults and adolescents with a body weight of more than 40 kg (aged 12 years and over).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Contraindications Buscofenact 400mg 20 soft capsules - When should Buscofenact 400mg 20 soft capsules not be used?\u003c\/h3\u003e\n\n \u003cp\u003eBuscofenAct soft capsules is contraindicated in case of: - hypersensitivity to ibuprofen or to any of the excipients listed in section 6.1; - history of hypersensitivity (e.g. bronchospasm, asthma, rhinitis, angioedema or urticaria) associated with the intake of acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs (NSAIDs); - haematological disorders of unknown origin; - history of recurrent or active peptic ulcer\/haemorrhage (two or more distinct episodes, with proven ulceration or bleeding); - history of gastrointestinal bleeding or perforation, related to previous therapy with NSAIDs; - cerebrovascular haemorrhage or other bleeding episodes; - severe heart failure (NYHA class IV) (see also section 4.4); - severe hepatic insufficiency or severe renal insufficiency (see also section 4.4); - patients in the third trimester of pregnancy (see section 4.6); - adolescents with body weight below 40 kg and children under 12 years of age; - patients with severe dehydration (due to vomiting, diarrhoea or insufficient fluid intake).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\n\u003ch3\u003e Quantity and method of taking Buscofenact 400mg 20 soft capsules - How to take Buscofenact 400mg 20 soft capsules?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cb\u003e\u003cu\u003eDosage\u003c\/u\u003e\u003c\/b\u003e Adults and adolescents with body weight \u0026gt; 40 kg (aged 12 years and over): Initial dose of 400 mg ibuprofen. If necessary, an additional dose of 400 mg ibuprofen may be taken. The interval between doses should be based on the symptoms observed and the maximum recommended daily dose, and should not be less than 6 hours. Do not take more than 1200 mg ibuprofen in 24 hours. For short-term treatment only. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). If BuscofenAct soft capsules must be taken in adults for more than 3 days in case of fever or for more than 4 days for the treatment of pain or if symptoms worsen, the patient is advised to consult a doctor. It is recommended that people with gastric disorders take it on a full stomach. If taken shortly after eating, the onset of the effect of BuscofenAct may be delayed. If this occurs, do not take BuscofenAct more than recommended in section 4.2 (dosage) or until the correct dose interval has elapsed. \u003cb\u003eSpecial patient populations\u003c\/b\u003e \u003cu\u003eElderly\u003c\/u\u003e No special dosage adjustments are required. Due to possible undesirable effects (see section 4.4), elderly patients should be carefully monitored. \u003cu\u003eRenal impairment\u003c\/u\u003e No special dosage adjustments are required in patients with mild or moderate renal impairment (for patients with severe renal impairment, see section 4.3). \u003cu\u003eHepatic impairment (see section 5.2)\u003c\/u\u003e No special dosage adjustments are required in patients with mild or moderate liver impairment (for patients with severe liver dysfunction, see section 4.3). \u003ci\u003ePaediatric population\u003c\/i\u003e BuscofenAct is contraindicated in adolescents with a body weight below 40 kg and in children under 12 years of age due to the high content of active ingredient (see section 4.3). If the use of the medicinal product is necessary for more than 3 days in adolescents, or in case of worsening of symptoms, a doctor should be consulted. \u003cb\u003e\u003cu\u003eMethod of administration\u003c\/u\u003e\u003c\/b\u003e For oral use. The soft capsules should not be chewed.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\n\u003ch3\u003e Storage Buscofenact 400mg 20 soft capsules - How to store Buscofenact 400mg 20 soft capsules?\u003c\/h3\u003e\n\n\u003cp\u003e This medicine does not require any special storage temperatures.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\n\u003ch3\u003e Warnings Buscofenact 400mg 20 soft capsules - About Buscofenact 400mg 20 soft capsules it is important to know that:\u003c\/h3\u003e\n\n \u003cp\u003eUndesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see sections below on gastrointestinal and cardiovascular risks). Caution is required in patients with certain clinical conditions, which may be exacerbated: - patients with systemic lupus erythematosus and various connective tissue diseases have an increased risk of developing aseptic meningitis (see section 4.8); - congenital disorder of porphyrin metabolism (e.g. acute intermittent porphyria); - gastrointestinal diseases and chronic inflammatory bowel diseases (ulcerative colitis, Crohn's disease) (see section 4.8); - hypertension and\/or cardiac impairment as renal function may deteriorate (see sections 4.3 and 4.8); - renal impairment (see sections 4.3 and 4.8); - hepatic dysfunction (see sections 4.3 and 4.8); - immediately after major surgery; - in patients with allergic reactions to other substances, since there is an increased risk of hypersensitivity reactions also following the use of BuscofenAct; - in patients suffering from hay fever, nasal polyps or chronic obstructive airway diseases since there is an increased risk of allergic reactions. These reactions may present as asthma attacks (so-called analgesic asthma), Quincke's oedema or urticaria. \u003cu\u003eGastrointestinal effects\u003c\/u\u003e The use of BuscofenAct soft capsules in combination with other NSAIDs, including selective cyclooxygenase-2 inhibitors, increases the risk of adverse reactions and should be avoided. \u003ci\u003eElderly\u003c\/i\u003e Elderly subjects have a higher frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). \u003ci\u003eGastrointestinal bleeding, ulceration or perforation\u003c\/i\u003e Gastrointestinal bleeding, ulceration or perforation, sometimes fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of GI events. If GI bleeding or ulceration occurs in patients receiving ibuprofen, the treatment should be withdrawn. The risk of GI bleeding, ulceration or perforation is increased with higher NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in elderly patients. These patients should start treatment on the lowest dose available. Concomitant therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients receiving concomitant low dose aspirin or other drugs likely to increase gastrointestinal risk (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) especially in the initial stages of treatment. Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5). NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as their condition may be exacerbated (see section 4.8). \u003cu\u003eSevere skin reactions\u003c\/u\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy; in fact, in the majority of cases, the reaction occurs within the first month of treatment. Acute generalized exanthematous pustulosis (AGEP) has been reported in relation to medicinal products containing ibuprofen. Administration of BuscofenAct soft capsules should be suspended at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Exceptionally, chickenpox may be the cause of serious skin infections and soft tissue complications. It is recommended not to use BuscofenAct soft capsules during chickenpox. \u003cu\u003eMasking of symptoms of underlying infections\u003c\/u\u003e BuscofenAct soft capsules may mask the symptoms of infection, which may delay initiation of adequate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When BuscofenAct soft capsules are administered for the relief of infection-related fever or pain, monitoring for infection is recommended. In non-hospital settings, the patient should seek medical advice if symptoms persist or worsen. \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e Caution is advised (discuss with your doctor or pharmacist) before initiating treatment in patients with a history of hypertension and\/or heart failure, since fluid retention, hypertension and oedema have been reported in association with NSAID therapy. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg daily), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg daily) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg daily) should be avoided. Careful consideration should also be exercised before initiating long-term treatment in patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), especially if high doses (2400 mg daily) of ibuprofen are required. \u003cu\u003eOther warnings and precautions\u003c\/u\u003e Severe acute hypersensitivity reactions (e.g. anaphylactic shock) have been observed very rarely. At the first signs of a hypersensitivity reaction following intake\/administration of BuscofenAct soft capsules, therapy should be discontinued. The required medical measures should be carried out by experienced personnel. Ibuprofen, the active ingredient of BuscofenAct soft capsules, may temporarily inhibit platelet function (platelet aggregation). Therefore, patients with platelet disorders should be carefully monitored. In case of prolonged treatment with ibuprofen, liver and kidney parameters as well as the blood picture should be checked regularly. Prolonged use of any analgesic for headache may worsen it. If this situation occurs or is suspected, the doctor should be consulted and treatment should be discontinued. The diagnosis of medication-overuse headache (MOH) should be suspected in patients with frequent or daily headaches despite (or because of) the regular use of headache medications. In general, the habitual use of analgesics, particularly the combination of different analgesic active ingredients, may lead to permanent kidney damage with the risk of renal failure (analgesic nephropathy). This risk may be increased under physical exertion associated with salt loss and dehydration. Therefore, this should be avoided. In case of concomitant alcohol consumption during the use of NSAIDs, adverse events related to the active ingredient, especially those affecting the gastrointestinal tract or the central nervous system, may increase. \u003cu\u003ePaediatric population\u003c\/u\u003e There is a risk of impaired renal function in dehydrated adolescents. Sorbitol BuscofenAct contains 95.94 mg of sorbitol in each capsule. Patients with hereditary fructose intolerance, a rare genetic disease, should not take this medicine.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Interactions Buscofenact 400mg 20 soft capsules - Which medicines or foods can modify the effect of Buscofenact 400mg 20 soft capsules? \u003c\/h3\u003e\n\n\u003ctable cellpadding=\"\" cellspacing=\"\" border=\"\"\u003e\n\n\u003ctbody\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eConcomitant use of ibuprofen with:\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e \u003cb\u003ePossible effects:\u003c\/b\u003e\n\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Other NSAIDs, including salicylates\u003c\/td\u003e\n\n\u003ctd\u003e Concomitant administration of several NSAIDs may increase the risk of gastrointestinal bleeding and ulcers due to a synergistic effect. Therefore, concomitant use of ibuprofen with other NSAIDs should be avoided (see section 4.4).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Digoxin\u003c\/td\u003e\n\n\u003ctd\u003e Concomitant use of BuscofenAct soft capsules with drugs containing digoxin may increase serum digoxin levels. Usually, if digoxin is used correctly (for a maximum of 4 days) it is not necessary to monitor serum digoxin levels.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Corticosteroids\u003c\/td\u003e\n\n\u003ctd\u003e Corticosteroids may increase the risk of adverse reactions, particularly of the gastrointestinal tract (gastrointestinal bleeding or ulceration) (see section 4.4).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Antiplatelet agents\u003c\/td\u003e\n\n \u003ctd\u003eIncreased risk of gastrointestinal bleeding (see section 4.4).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Acetylsalicylic acid\u003c\/td\u003e\n\n\u003ctd\u003e Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Anticoagulants\u003c\/td\u003e\n\n\u003ctd\u003e NSAIDs may increase the effects of anticoagulants, such as warfarin (see section 4.4).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Phenytoin\u003c\/td\u003e\n\n \u003ctd\u003eConcomitant use of BuscofenAct and phenytoin preparations may increase serum phenytoin levels. Usually, if used correctly (for a maximum of 4 days) it is not necessary to monitor serum phenytoin levels.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Selective serotonin reuptake inhibitors (SSRIs)\u003c\/td\u003e\n\n\u003ctd\u003e Increased risk of gastrointestinal bleeding (see section 4.4).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Lithium\u003c\/td\u003e\n\n\u003ctd\u003e Concomitant use of BuscofenAct with lithium preparations may increase serum lithium levels. Usually, if used correctly (for a maximum of 4 days) it is not necessary to monitor serum lithium levels.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Probenecid and sulfinpyrazone\u003c\/td\u003e\n\n\u003ctd\u003e Drugs containing probenecid and sulfinpyrazone may delay the elimination of ibuprofen.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Diuretics, ACE inhibitors, beta-blockers and angiotensin II antagonists\u003c\/td\u003e\n\n \u003ctd\u003eNSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (especially dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor, a beta-blocker or angiotensin II antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, these combinations should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function at the start of concomitant therapy and periodically thereafter.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Potassium-sparing diuretics\u003c\/td\u003e\n\n\u003ctd\u003e Concomitant administration of BuscofenAct and potassium-sparing diuretics may lead to hyperkalemia.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Methotrexate\u003c\/td\u003e\n\n \u003ctd\u003eBuscofenAct administered within 24 hours before or after taking methotrexate may increase its concentrations and therefore its toxicity.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Cyclosporin\u003c\/td\u003e\n\n\u003ctd\u003e The risk of renal damage induced by ciclosporin may be increased by concomitant use of some NSAIDs. This effect cannot be excluded in case of concomitant intake of ciclosporin and ibuprofen.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Tacrolimus\u003c\/td\u003e\n\n\u003ctd\u003e The risk of nephrotoxicity increases with concomitant administration of ibuprofen and tacrolimus.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Zidovudine\u003c\/td\u003e\n\n\u003ctd\u003e When ibuprofen and zidovudine are administered concomitantly, there is evidence of an increased risk of haemarthroses and haematomas in HIV-positive haemophiliacs.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Sulfonylureas\u003c\/td\u003e\n\n\u003ctd\u003e Clinical studies have shown that there are interactions between nonsteroidal anti-inflammatory drugs and antidiabetic drugs (sulfonylureas). Although no interactions between ibuprofen and sulfonylureas have been described so far, in case of concomitant use of these two drugs it is advisable to monitor blood sugar levels.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Quinolone antibiotics\u003c\/td\u003e\n\n \u003ctd\u003eAnimal studies indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of developing seizures.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e CYP2C9 inhibitors\u003c\/td\u003e\n\n\u003ctd\u003e Concomitant administration of ibuprofen and CYP2C9 inhibitors may increase the exposure to ibuprofen (CYP2C9 substrate). In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)-ibuprofen by approximately 80% to 100% was observed. Consideration should be given to reducing the ibuprofen dose when strong CYP2C9 inhibitors are co-administered, particularly when high doses of ibuprofen are administered with voriconazole and fluconazole.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Mifepristone\u003c\/td\u003e\n\n\u003ctd\u003e NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs may reduce the effect of mifepristone.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\n\u003c\/tbody\u003e\n\n\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e\n\n \u003ch3\u003eLike all medicines, Buscofenact 400mg 20 soft capsules can cause side effects - What are the side effects of Buscofenact 400mg 20 soft capsules?\u003c\/h3\u003e\n\n \u003cp\u003eThe list of undesirable effects reported below refers to all undesirable effects that have been reported during treatment with ibuprofen, including those observed during long-term and high-dose treatment in patients with rheumatic diseases. The reported frequencies, which occur with an incidence greater than very rare cases, refer to the short-term use of daily doses of up to a maximum of 1200 mg of ibuprofen for the oral dosage form and a maximum of 1800 mg for suppositories. It should be taken into account that the following undesirable effects are essentially dose-dependent and vary from individual to individual. The most commonly observed undesirable events are gastrointestinal in nature. Peptic ulcer, perforation or gastrointestinal haemorrhage, even with fatal outcome, may occur, especially in the elderly (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, worsening of colitis and Crohn's disease have been reported following administration (see section 4.4). Gastritis has been observed less frequently. The risk of gastrointestinal bleeding depends on the dose and duration of treatment. Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg daily), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Patients should be advised to stop taking BuscofenAct immediately and to consult their doctor if a serious adverse reaction occurs. Adverse reactions are listed below by system organ class and frequency, using the following categories: Very common (≥1\/10) Common (≥1\/100, \u0026lt;1\/10) Uncommon (≥1\/1000, \u0026lt;1\/100) Rare (≥1\/10,000, \u0026lt;1\/1000) Very rare (\u0026lt;1\/10,000) Not known (cannot be estimated from the available data)\u003c\/p\u003e\n\n\u003ctable cellpadding=\"\" cellspacing=\"\" border=\"\"\u003e\n\n\u003ctbody\u003e\n\n\u003ctr\u003e\n\n \u003ctd\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e In association with the use of nonsteroidal anti-inflammatory drugs, worsening of infectious inflammation (e.g. development of necrotizing fasciitis) has been observed. This is probably associated with the mechanism of action of nonsteroidal anti-inflammatory drugs. Symptoms of aseptic meningitis with stiff neck, headache, nausea, vomiting, fever or blurred consciousness have been observed during treatment with ibuprofen. Patients with autoimmune diseases (SLE, mixed connective tissue disease) appear to be predisposed.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003ePathologies of the haemolymphopoietic system\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Hematopoietic disorders (anemia, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis). The first signs may be: fever, sore throat, superficial sores in the mouth, flu-like symptoms, severe tiredness, nosebleeds and skin bleeding. In long-term therapy, blood counts should be monitored regularly.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n \u003ctd rowspan=\"\"\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Hypersensitivity reactions with skin rashes, itching, asthma attacks (with possible drop in blood pressure).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Severe generalized hypersensitivity reactions, signs of which may include facial edema, swelling of the tongue, swelling of the larynx with constriction of the airways, respiratory distress, tachycardia, drop in blood pressure, up to life-threatening shock. If any of these symptoms occur, and this can happen even on the first use, immediate medical attention is required.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003ePsychiatric disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Psychotic reactions, depression.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eNervous system disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Central nervous system disorders, such as headache, dizziness, insomnia, agitation, irritability or tiredness.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eEye pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Visual disturbances.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eEar and labyrinth pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Tinnitus.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eHeart disease\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n \u003ctd\u003ePalpitations, heart failure, myocardial infarction.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eVascular pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Arterial hypertension, vasculitis.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"\"\u003e \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Common\u003c\/td\u003e\n\n\u003ctd\u003e Gastrointestinal disorders, such as heartburn, abdominal pain, nausea, dyspepsia, vomiting, flatulence, diarrhea, constipation, slight gastrointestinal blood loss which in exceptional cases leads to anemia.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Gastrointestinal ulcer with potential for haemorrhage and perforation. Ulcerative stomatitis, worsening of colitis and Crohn's disease (see section 4.4), gastritis.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Esophagitis, pancreatitis, diaphragmatic intestinal stenosis formation. If severe pain in the upper abdomen is felt or if melena or hematemesis occurs, it is recommended to inform the doctor immediately and stop taking the medicine.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eHepatobiliary pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Liver dysfunction, liver damage, especially in case of prolonged therapy, liver failure, acute hepatitis.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n \u003ctd rowspan=\"\"\u003e\u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Various skin rashes.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Bullous reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome), alopecia. In exceptional cases, serious skin and soft tissue infections may occur during chickenpox infection (see also \"Infections and infestations\").\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e Acute generalized exanthematous pustulosis (AGEP). Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). Photosensitivity reactions\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"\"\u003e \u003cb\u003eKidney and urinary disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Rarely, damage to the kidney tissue (papillary necrosis) and high concentrations of uric acid in the blood may also be observed.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Formation of edema, especially in patients with arterial hypertension or renal insufficiency, nephrotic syndrome, interstitial nephritis, which may be accompanied by acute renal failure. Renal function should be monitored regularly.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\n\u003c\/tbody\u003e\n\n\n\u003c\/table\u003e\n\n \u003cp\u003eIf necessary, patients should be adequately informed to stop treatment with BuscofenAct and consult a doctor immediately if any of the following conditions occur: - severe gastro-intestinal disturbances, heartburn or abdominal pain; - haematemesis; - melaena or blood in the urine; - skin reactions, such as itchy rashes; - respiratory distress and\/or swelling of the face or larynx; - fatigue associated with loss of appetite; - sore throat, associated with aphthous ulcers, fatigue and fever; - severe nosebleeds and skin bleeding; - abnormal tiredness associated with reduced urine output; - swelling of the feet or legs; - chest pain; - visual disturbances. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eOVERDOSE\u003c\/h2\u003e\n\n\u003ch3\u003e Buscofenact 400mg 20 soft capsules Overdose - What are the risks of Buscofenact 400mg 20 soft capsules in case of overdose?\u003c\/h3\u003e\n\n\u003cp\u003e \u003cu\u003eSymptoms in case of overdose\u003c\/u\u003e Symptoms of overdose may manifest themselves with central nervous system symptoms such as headache, dizziness, light-headedness and loss of consciousness (myoclonic convulsions even in children), abdominal pain, nausea, vomiting, gastrointestinal bleeding and liver and kidney dysfunction, hypotension, respiratory depression and cyanosis. In cases of severe poisoning, metabolic acidosis may occur. \u003cu\u003eTherapeutic measures in case of overdose\u003c\/u\u003e There is no specific antidote. If after one hour of ingestion, the patient has potentially toxic levels of the drug, resort to oral administration of activated charcoal.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\n \u003ch3\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Buscofenact 400mg 20 soft capsules.\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage, cardiac malformations and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformations increased from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor resulted in increased pre- and post-implantation loss and embryo-foetal mortality. In addition, an increased incidence of malformations, including cardiovascular, has been reported in animals treated with a prostaglandin synthesis inhibitor during the organogenesis period. During the first and second trimester of pregnancy, ibuprofen should be administered only if clearly necessary. If ibuprofen is used in women attempting to conceive or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to the risk of: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligo-hydroamnios. At the end of pregnancy, the mother and the neonate are at: - possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses; - inhibition of uterine contractions which may result in a delay or prolongation of labor at delivery. Consequently, the administration of ibuprofen is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Ibuprofen and its metabolites may pass into breast milk in low concentrations. To date, no deleterious effects on nursing infants are known. Therefore, for short-term treatment of pain and fever at the recommended dose, it should not generally be necessary to stop breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e There is some evidence that drugs which inhibit cyclooxygenase\/prostaglandin synthesis may impair female fertility by affecting ovulation. Once treatment with ibuprofen has been stopped, the effect is reversible.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\n\u003ch3\u003e Taking Buscofenact 400mg 20 soft capsules before driving or using machines - Does Buscofenact 400mg 20 soft capsules affect driving or using machines?\u003c\/h3\u003e\n\n\u003cp\u003e Since the intake of BuscofenAct at the highest dosage may cause undesirable effects on the central nervous system, such as tiredness and dizziness, in isolated cases the ability to react promptly, the ability to drive and to use machines may be impaired. This applies especially if the use of BuscofenAct is associated with alcohol consumption.\u003c\/p\u003e","brand":"SANOFI SpA","offers":[{"title":"Default Title","offer_id":51131368669511,"sku":"041631033","price":13.86,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-buscofenact-400mg-20-capsule-molli-farmacia-dottor-tili-1213791894.jpg?v=1767150345"}],"url":"https:\/\/www.dottortili.com\/en-eu\/collections\/buscopan.oembed?page=2","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}